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.
ABSTRACT
Schatz, Robert Alfred. Ph. D., University of Rhode Island, June, 1972.
Pargylin e, Succinic Acid and L-Ascorbic Acid as Protective Agents Against
Hyperbaric Oxygen Toxicity: Possible Involvement of Altered GammaAminobutyric Acid and Ammonia Metabolism .
The mechanisms whereby pargyline, succinic acid and ascorbic acid
p rotect againot hyperbaric oxygen convulsions, pulmonary damage and
mortality

follo ~i ng

hyperbaric oxygen exposure were investigated in re-

l ation to the effects of these agents on hyperbaric oxygen- induced
alterations in brain gamma-aminobutyric acid and ammonia metabolism .
Exposure to hyperbaric oxygen (60 pounds per square inch, gauge
p ressure) produced convulsions, post-exposure lethality and elevation in
lung weight, lung water content and lung hemoglobin cont ent .

Pargyline,

succinic acid and ascorbic acid provided part:i.?.l protection against al l
o f the above aspects of oxygen toxicity.
Compari son of the doses of pargyline ,

s~ cc inic

acid and ascorhic

acid that provi d8d maximal protect i on against hyperbaric oxygen convulsio ns shewed that aJ. l three agents were approximately equal , in the
dos es used, with respect to their effectiv eness in decreasing the incidence of hyperbaric oxygen convulsions and increas ing the latency to
th eir onset.

Pargyli>le and succinic acid \·?ere approximately equal, in

th e doses used, in their ability to reduce post-exposure lethality and
hyperbaric oxygen-induced increases in lung weight , water content and
h emoglobin content.

Ascorbic acid was less effective in its ability to

reduce th e above changes induced by hyperbaric oxygen exposure.
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Hyperbaric oxygen decreased brain gamma-aminobutyric acid levels.
This decrease was due to inhibition of glutamic acid decarboxylase without
any effect on gamma-aminobutyric acid transaminase activity .

Both

pargyline and succinic acid increased brain gamma-aminobutyric acid levels
in room air-exposed mice and prevented the decrease in brain gammaaminobutyric acid produced by hyperbaric oxygen exposure.
increas ed gamma-aminobutyric acid levels by inhibiting

Pargyline

gamma-2~1inobutyric

acid transar:iinasc activity in room air- and hyperb2ric oxygen-exposed
n:ice.

S1Jccinic acid increased the activity of both glutamic acid dec ar-

boxylase and ganma-ao in ob utyric acid transaminase, glutamic acid deca rboxylase to a greater degree than gaIILma-arninobutyric acid transaminase.
Glut amic acid dec a rboxy lase activity was still slightly increased in
mice exposed to hyperbaric oxygen .

These alterations in enzyme activity

\7ere responsible for the ability of pargyline and succinic acid to
increase brain ganuna- aminobutyric acid l evels in room air-exposed mice
and to prevent the hyperbaric oxygen-induced decrease in brain gammaaminobutyric acid in animals exposed to hyp e rbaric oxygen.

There was a

significant correlation between hyperbaric oxygen seizure susceptibility
and brain

garr~1a -arai.nobutyric

acid levels in pargyline- or succinic acid-

treat e<l mice .
In pargyline- or succinic acid-treated mice there was a doseresp onse relationship between amount of c.lrug administered and degree of
elevation in brain garnma-aminobutyric acid .
Ascorbic acid had no effect on brain gamma-aminobutyrjc acid levels
nor did it prevent the hyperbaric oxygen-induced decrease in brain garnmaam inobutyric acid.

Ascorbic acid tr eatment had no effect on glutamic acid

iii

decarboxylase or gamma-aminobutyric acid trans am inase activities nor
did it prevent the hyp e rbaric oxyge n-induced decrease in glutamic acid
decarboxylase activity.
Hyperbaric oxygen exposure increased brain ammonia levels and
decreas ed brain glutamine levels.

All three agents reduced these

typerbaric oxygen-induced alterations .

There was a correlation be-

t ween brain ammonia leve ls and hyperbaric oxygen seizure susceptibility
in nice

treat~d

with pargyline , succinic ac id or ascorbic acid.

The

same was true f or glutamine lev e ls and hyperbaric: oxygen seizure susce ptibility .
These

n~sults

demon strate tha t decreased gamma-aminobutyric acid

l evels and increas ed am.mania leve ls in the brain are involved in the
etiology of hyperb ar ic oxygen toxicity .

The effect iveness of the

three agents tested as protective agents

aga in~ t

hyperbaric oxygen

toxic ity appears relat ed to their ability to alter the hyp erbaric
oxygen- induced chanse s in brain nmmonia and gamrna-aminobutyric acid
metabolism.
The relationship between hyperb ar ic oxygen- induced alte rations in
gamma-aminobutyric acid and ammonia metabolism and th e effects of pargyline, succinic acid and ascorbic acid thereon are discussed with
respect to mitochondrial function and consequent ad enos ine triphosphate
production.

To:
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LIST OF ABBREVIATIONS USED
ATP

adenosine tripho sphate

CNS

central nervous system

DA

dop amine

GABA

gamma-aminobutyric acid

GABA- T

gamma-aminobutyric acid trans aminase (EC 2 . 6 . 1 .19)

GAD

L-glutamic acid decarboxy lase (EC 4 . 1 .1.1 5)

GLDII

L-glutamic acid dehydrogenase (EC 1.4 . 1 . 2)

5-HT

serotonin

a-KG

alpha-kctoglutaric acid

OHP

hyperbaric oxyg en

MAO

monoamine oxidase (EC 1.4.3.4)

NADH

reduc ed nicotinamide adenine dinucleotide

NADP

nicotinamide adenine dinucleotide phosphate

NE

norepinephrine

psig

pounds per square inch (gauge pressure )

Pyr P

pyridoxal phosphate
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I.

INTRODUCTION

With man's increasing quest for knowledge and search for natural
resources other than those found on land, it is becoming more and more
likely that man will encounter greater than norma l par tial pr ess ures of
oxyg en i n various situations such as diving operations , space tr avel and
us e of hyperbarlc oxygen in medicine.
In th e field of medicine , OHP is being emp loyed in t1 1e treatmen t
of myocardial
~l·,

1966).

infar~tion
Us~

(Peter

~

~

o f OHP to extend the s a fe-period cf circulatory arres t

during sur gery (He i jne, 1966; Moo1:
i ta l card iac defects
s aving procedure .

.§..!_., 196 6 ) a nd shock (DelGuercio

.§..!_., 1966), psrt icularly of congen-

~

( Ber~ h ard ~al.,

1966), has been considered a life-

OHP has also been us e d in the treatment of anaerob ic

infecticns (Hitchco ck e t_ al., 196 7; Jones, 196 7; Brummelkamp , 1966), in
burn th erapy (Taber, .196 7; Nelson
(Chur ch~ll-Davidson ,

~

al. , 1966), in cancer chemo therapy

1966; Nathanson et al., 1966) an d in treat ment of

carbon monoxide and cyanide poisoning (Norman

~

.§..!_. , 1970; Shene et al_.,

1966).

For these reasons , man has become increa singly aware of the po3sible value of OHP in many aspects of modern life .

Man h a s, howeve r, also

become awa re of the tox ic effects of OHP , which includ e muscle fasciculations, convulsions, pulmonary damage and pos t--expos ure lethality.
In recent year s , investigators have begun to explore the mechanism(s) of this tox ic syndrome by using , as tools, drugs that ameliorate
one or more of th e asp ec ts of OIIP to xicity.

This approach will
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provide us with furth e r insight and information regarding the cellular
mecha nism(s) of OHP tox icity.

Furthe r, a drug capab le of providing pro-

te ction against OHP toxici ty will be of i mmense value in that it wi ll
permit wid e r and more frequ ent use of OHP in a variety of clinical condition s and may also preve nt any tox ic effects occurring during the
course of undersea and aerospace exp loration.
We have selected to study the effects of th ree agents.

The pro-

t ective e ff ec ts of two of these ag en ts against s ome of the aspects of OHP
t oxicity a r e we ll doclllnent ed .
et

~l ·,

1969).

1969 ; Faiman

~al.,

Sin ce preliminary

These two agents are pargy line (B lenkarn

1971) and succinic acid

investig a~io~s

( Sanders~..§.!. .,

revealed that L-ascorbic acid

protecred a ga in s t OHP convulsions and since very little previous work
h ad be en done with this age nt in the area of OHP toxic ity, we included
a scorbic acid in our i nvestigation.
The protective effect of pargyline against OHP convulsions was
or iginally thought to be due to th e ability of this ag ent to elevate
brain amines (NE, 5-HT and DA) si".1ce it had previously been sho'.m that
OHP exposure decreased brain NE and 5-HT (Faiman and Heble, 1966) .
Subsequent invest ig ation revealed that the protective effect of the
MAO inhibito rs was not altered by amine prec ursors or amine synthesis
inhib itors (Blenkarn

~

al. , 1969; Faiman

~

al. , 19 71) .

The conclusion

reached by both groups of investigators was th at th e protective effect
of MAO inhibitors was unrelated to altere d turnover rat e s or absolute
brain levels of the se amines (Blenkarn et al ., 1969; Faiman et al .,
1971).

Va rious MAO inhibitors have been shown to elevate b rain GABA
levels (Balzer

~

..§1_., 1960; Popov and Hattheis , 1969) and decreased
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levels of brain GABA have been shown to be involved in the etiology of
OHP convulsions (Wood, 1970).

There have been many reports in recent

years concerning the role of GABA as an inhibitory trans mitter in the
CNS (Rob erts, 1962; Kravitz, 1967).

Asids from the fact that GABA's

role as a CNS transmitter has not yet been clearly elucidated, it has
been shown to have definite neuronal inhibitory properties in the CNS
(Roberts, 1962; Kravitz, 1967) and by virtue of this, may be expected
to pl ay a rol e in the etiology of convulsive episodes.

In brief , the

main points th at support this hypothesis are the facts that OHP decreased GABA , the decrease was specific for GABA and occurred prior to
OHP convulsion s and GABA administration prevented OHP convulsions
(Wood, 1970).
It is nm.,r well accepted that ammonia is a convulsant agent
(i/ o] fe and Elliott, 1962).

Further, br Qin ar.lillonia hc:s been shown to be

significantly elevated during OHP expos ure (G ershenovich and Krichenskoya, 1954; Szam, 1969) and the greatest elevation occurred concurrently with the onset of OHP convulsions (Gershenovich and Krichenskoya,
1954).

The MAO inhibitors may prevent the contribution of &-nmonia to

the ammonia pool by preventing the enhanced catabolism of biogenic
amines (Faiman and Heble, 1966) or inhibition of the Krebb 's cycle by
OHP (Dickens , 1962) which may reduce the flow of ammonia acceptors
resulting in an elevation in brain ammonia .
This investigation was undertaken to investigate the effects of
the aforementioned drugs on various aspects of OHP toxi city with respect
to the possibl e involvement of altered brain GABA and/or &-nmonia metabolism in the protective phenomenon.
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The hypotheses to be tested are :
1.

The p rotective effect of pargyline , succinic acid and ascorbic
a ci d against OHP toxicity is related t o the ability of these agents
to prevent the OHP-induced decrease in brain GABA levels .

This

e ffec t on brain GABA is mediated by increased synthesis and / or
decreased degradation of GABA .
2.

The protective effect of pargyline, succinic acid and ascorbic ac id
is also related to the ability of these agents to pr even t the ORPi nduced elevation in brain ammonia and decrease in brain glutamine
l evels .

3.

I n addition to the protective effect of these agents on OHP convuls ions, pargyline, succinic acid and ascorbic acid also proteclagainst OHP-induced pulmonary damage and post- OHP mortality .
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II.

LITERATURE SURVEY

HYPERBARIC OXYGEN CONVULSIONS
The most dr amatic manifestation of oxygen toxicity at pressures in
excess of 2 to 3 ATA (33 to 66 ft) is .the onset of convulsions.

The

first r eport concerning the effects of exposure to OHP was that of
Bert (1878), in which he described in detail the incidence of convulsions in various animal species exposed to hyperbaric o:<.ygen .
was subsequently confinned by nurr,erous other investigators
has been reviewed by Bean (1945) and Haugaard (19 68).

1his

wl~ose

\:ori~

work

Tr,e seizures take

t he form of generalized convulsions which are frequently, but not always,
preceded by minor twitching of the head and forelimbs.
OHP convulsions have also been reported to occur j_n man ( Behnke
~al.,

1934-5).

Lambertsen (1965) described the course of progressive

s ymptoms as follows :
The convulsions are usually but not always preceded
by the occurrence of localized muscular t witching ,
especially about th e eyes, mouth and forehead. Small
muscles of the h ands may be involved and incoordination
of diaphragm activity in respiration may occur . These
ph enomena increas e in severity over a period which may
vary from a few minutes to nearly an hour with essentially
clear consciousness being retained . Eventually an abrupt
spread of excitation occurs and the rigid tonic pha~e of
the convulsion begins. The t onic phase lasts for about
30 secs and is accompanied by an abrupt loss of consciousness. Vigorous clonic contraction s of the muscular groups
of head and neck, trunk and limbs then occur becoming
progressively less violent over abcut one minute .

12
HYPERBARIC OXYGEN-INDUCED PULMONARY DAMAGE
Smith (1899) carried out the first extensive investigation
on the effect of in creased oxyge n tensions on the lungs of animals.

He

showed that oxygen was a lung irritant producing inflamma tion and congestion and that these effects occurred at partial pressures of oxygen less
than those r equired for the ons et of convulsions.

At pressures less t han

0.7 ATA oxyg en , damage occurred very slowly , if at all , and greater than
3 ATA, there was the oversha dowing onset of convulsions .

Clark and

Lambertsen ( 1971) have recently reviewed pulmonary oxygen tox ic ity .
The overt sign of lung damage in OHP-exposed animals was the occurrence of dyspne a (Gesell , 1923;

Paine~ a~. ,

1941).

Gross

ex~rrina tion

c f lungs showed pulmona ry damage consisting of extensive areas of hemorrhage and edema (Karsner , 1916; Karsner and Ash , 1917).
r~porte<l

the occurrence of congestion, edema , epithellal

Karsner (1916)
deg~neration

and. desquamation , fibrin fonna tion and pneumonia in rabbi ts exposed to
80- 90 percent oxygen for 24-48 hours.

Thickeniug and hyalinization of

the walls of the pulmonary arteries was observed by Smith et al (1932),
and the occurrence of atelectasis in the lun gs of exposed animals has
also been clearly established

(B ehnke~

al ., 1934; Van Den Brenk and

Jamieson , 1962) .
POSSIBLE RELATIONSHIP BET~·1 EEN HYPERBARIC
OXYGEN-INDUCED CO \!VULSIONS A1~D PULMONARY DAi.\fAGE
The studies of Smith (1899) demonstrated that pulmonary pathology
occurred in the absence of OHP convulsions.

Further, pulmonary damage

occurred during relatively short periods of exposure to OHP (2-3 AtA)
(Bean and Johnson, 1955), although the onset of s eizures was the most
dramatic sign of OHP toxicity at these high pressures ( Stadie

~

al.,

13
1944) .

The observations of Johnson and Bean (1957) and

Wood~

al .

( 1965) that lung dama ge occurre d in animals tha t had suffered severe
seizur es raised the po ss ibility that there may be a cause and effect
relationship between s e izur es and this r apidly developing pulmonary
damage.
This pos sible relationship was discounted by Shilling and Adams
(1933) when they found that pentobarbital e limi na t ed seizures but not
l ung damage in Q}fP-exposed rats and th a t no lung damage occurred after
ch emic ally induced (st rychn ine ) seizures .

J amieson an d Van Den Brenk

(1962), h owever , fo und pentob arbital to be as effective in reducing
lung damag e as it was in preventing the on set of seizures.

Further,

s evere lung damage has b een reported after sei zures induced by thios emicarbazide (Tennekoon, 1954) or pentylenetetrazo l (Riecher t, 1941).

Bean

et al. (1966) found th a t anaesthetic agents protected against both
seizures and lung damage induced by chemical ag ents

01

Oi:IP wh e reas

sympatholytic agents protected against only pulmonary pa thology .

These

investigators suggested that pulmonary damage was largely th e result of
some neuroendo crinogenic component of the seizure .
It is still not established whether slow or rapid OHP-induced

pulmonary damage are brought about by the same mecha nism, but microscopic
examinatio~

of both type s of lung r evealed li ttle qualitative differenc£

between the two types of lung damage (Van Den Brenk and Jamie son, 1962) .
It may be tha t development of pulmona ry damage at less than 2 ATA oxygen
involves the sympathetic nervous system and tha t onset of seizures at
high er oxygen pressures stimulates this portion of the nervous system
thereby hastening the onset of lung damag e.
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EFFECT OF ALTERATION OF BRAIN AHINES ON SEIZURE SUSCEPTIBILITY
Schlesinger

~~

al. (196 5) found siguificant differences in brain

5-HT and NE in mice of certain seizure-susceptible strains (DBA/2J),
relative to seizure-resistant mice (C57Bl/6J), at the age when seizure
incidence was maximal (2 1 days).

These investigators (S chlesinger et

al., 1968) also observed that agents that l owered brain amines (r eserpine , alpha-methyl-p-tyrosine, p-chlorophenylalanine) increased the susceptibility of mice to audiogenic seizures, while agents which increas e
brain amines (H,.'\O inhibitors, 5-hydroxytryptophan) had a protective
effect agRinst audiogenic seizures.

MAO inhibitors have been reported

to inhibit various components of audiogenic seizures (Plotinkoff
1963).

~ ~~ ·

,

Lehman (1967) observed that HAO inhibitors tendE.:d to protect

agains t audiogenic seizures in mice, while reserpine iL1creased their
severity.
Reserpine, which releases brain amines, enhanced electroshock convulsions, while MAO inhibitors, which increase brain am ines, pro tec t ed
against these convulsions

(Prockop,

~

.:il. , 1959).

Exposure to OHP

lowered NE in both mouse (Faiman and Heble, 1966) and rat (Haggendal ,
1967; Haggendal , 1968) brain.

Brain 5-HT was decreased in mouse (Faiman

and Heble, 1966 ) and inc reased in rat (Haggendal , 1968) .

Reserpine

shortened the time to ons et of OHP convulsions in mice (Haggendal , 1968;
O liver~

al ., 1970) , while the MAO inhibitors nialamide (Haggendal ,

19 68 ), i proniazid and pargyline increased the latency to OHP seizures
(Blenkarn

~ ~ ·,

1969) .

From the preceding it would appear that brain amines play a role
in OHP-induced convulsions , but this was not found to be the case after
subsequent investigation.

Inhibitors of NE synthesis (alpha-methyl-p-
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tyro sine ) and 5- HT (p-chlorophenylal anine ) lowered brain NE and 5-HT
content but had no effect on OHP tolerance in rats (Blenkarn
1969) or mice (Faiman

~al.,

1971).

~

al.,

The amine precursors 5-hydroxy-

tryptophan elevated 5-HT levels and 3,4-dihydroxyphenylalanine elevated
NE and DA levels without producing any significant effect on OHP
tolerance in rats (Bl enkarn
1971).

~

al. , 1969) or mice (Faiman

~

Inhibition of dopamine- B-oxidase (EC 1.14.2.1) by disulfuram

elevat e d brain DA levels and incre ased OHP tolerance (F aiman
1971).

al. ,

~

al. ,

Our preliminary invest ig ations , however , demonstrated th a t the

dop am ine- B -oxida~e

tol erance .

inhibit o r diechyldithiocarbama te did not alter OHP

Further, since disulfur am , upon absorption, has been shown

to be converted to its corresponding thiol diethy ldithiocarb ama te
(Stromme , 1965) and since di.ethyldithiocarbama te did not provide any
significant protection against OHP convuisions , it appears that the
protet:tive effect of disulfuram is not due . to

i~hibition

of dop amine-

B-oxidase or subsequent elevation of brain DA levels.
Altered

turnov~r

rates of NE and 5-HT have also been implicated

in the etiology of the OHP-induced convulsion (Faiman and Heble, 1966;
Haggendal, 1967, 1968; Neff and Costa, 1967;

Diaz~

al., 1965).

Blenkarn and coworkers (1969), however, concluded from their studies
that a direct relationship between OHP central nervous system toxicity
and 5-HT or NE turnover rates did not exist in rats.

Since the findings

of Faiman et al. (1971) in mice concur with tho se of Blenkarn et al.
(1969), the same may be said to be true in the case of mice .
It appears, therefore, that no dir e ct correlation exists between
OHP convulsions and NE or 5-HT levels or turnover rates in rat or mouse
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brain.

As will be seen in the following section , this may also be t rue

in th e case o f electroshock and audiogenic seizures .
GAMMA-AMINOBUTYRIC ACID AND HYPERBARIC OXYGEN
Wolfe and Elliott (1 962 ) have revi ewed the evidence for the role of
GABA in convulsions induced under a wide variety of conditions .

Al though

the rol e of GABA in the brain is not totally understood, a variety of
evidence points toward its
1962) .

neuro~al

inhibitory properties (see Roberts ,

There is considerable evidence for the involvement of GABA in

the causation of seizures induce d by OHP exposure.

This evidence can be

summarized as fellows :
1.

Exposure of animals to OHP de creased brain GABA (Wo od g
Wood g

2.

al., 1963;

al. , 196 7).

The decreased GABA and OHP convulsions were r eversible (Wood and
Watson, 1963).

3.

The decrease in GABA occurred prior to convulsions (Wood and Watson,
1963).

4.

Of the amino acids t ested , the decreas e was specific for GABA (Wood
and Watson, 1963) .

5.

Susceptibility to OHP convulsions correlated well with the rate of
decline in brain GABA for differ ent species, different pressures of
oxygen and diff eren t stages of developmen t (Wood g

al. , 196 7; Wood

et al., 1969 ).
6.

GABA administration protected animals against OHP convulsions (Hood
et al. , 1963; Wood et al. , 1966; Wood and Watson , 1968; \food, 1970).
The metabolic pathway of GABA is shov.m in Figure 1.

Glutamic acid

is metabolized to GABA by GAD and GAHA is then converted to succinic
s emialdehyde by GABA-T .

The final step in t he pathway i s the convers ion
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glut am ina.se
GLUTAMINE
glutamine
s yn thetase

~

-~

.

'>l

+

>-

GLUTAMIC ACID

NH4

ATP

~NH1;

GLUTAHIC ACID

-<--~~~~~-

a-KETOGLUTARIC ACID

glu tamic acid
decarboxylase
Pyr P
y-AMINOBUTYRIC ACID
y-aminobutyric acid
transaminase
Pyr P
SUCC INIC ACID

Figure 1.

GAMMA-Ai'v!INOBUTYRI C ACID-GLUTA'HNE PATHWAY IN BRAIN
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of succinic semialdchyde to succinic acid by succinic semialdehyde dehydr ogenase ( EC 1.2.1.16).

Both GAD and GABA-Tare Pyr P dependent

enzymes (s ee Baxter, 1970).
The decrease in brain GABA levels during OHP exposure has been
shown to be due to inhibition of GAD (Wood
1968).

~

al., 1967; Myles and Wood,

OHP had no effect on either GABA-Tor succinic semialdehyde

dehydrog enase

(Wood~

al., 1967; Myles and Wood, 1968).

Previously, phenelzine (Popov and Mattheis , 1969) and ipro niaz id
(Balzer

~_al.,

1960) , two inhibitors of XAO structurally unrel ated to

pa:::-gyline, were repor ted to elevate brain GABA.

The elevation in brain

GABA after phenelzine was due to inhi bition of the GABA degrading enzyme
GABA-T (Po pov and Mattheis, 1969) .
vulsions (Blenkarn

~~·,

These drugs protect against OHP con-

1969; unpublished data).

Reserpine dec r eased

bo th brain GABA (Balzer

~

(Oliver et al ., 1970).

Iproniazid prevented both the decrease in the

al., 1960) and the latency to OHP convulsions

threshold to electroshock seizures and the decrease in brain GABA caused
by reserpine (Balzer

e~

al., 1960).

Amino-oxyacetic acid elevated brain

GABA, protected against audiogenic seizures

(S chlesinger~

al., 1968)

and decreased the incidence of severe OHP convulsions (Wood and Watson,
1962).
From the preceding , it appears that maintenance of normal brain
GABA levels is an important factor in the susceptibility of animals to
audiogenic, electro s hock or OHP seizures and that the protective effects
of the MAO inhibitors on these three seizure types may be a consequence
of their ability to maintain normal levels of brain GABA .
AMMONIA
The GABA precursor , glutamic acid, is also the precursor to
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glutamine.

Glutamine synthesis (s ee Figure 1) is the brain's ammonia

detoxic a tion mechanism and thus is important in maintaining the intracellul ar ammonia levels within a certain range (Katunuma

~

al. , 1965) .

As mentioned in the introduction, ammonia is a convulsant agent
(see Dickens, 1962).
acetat e

Elevated brain ammonia levels produced by ammonium

( Ugarte~~ ·,

1968) or ammonium chloride (S alvatore and

"
" . ,
Bocchini, 1961) caused convulsions and pulmonary edema (Konig
and Konig
1949).

Ammonia leve ls were increased during OHP exposure (G e rshenovich

and Krichenskoy a , 1954; Szam, 1969) and neutralized ammon i um chloride
tended to

1966).

decre a::;._~

the l a tency to OHP convulsions (Gottleib and Cymerman ,

Gersh enovich and Krichenskoya (195f1) foun d that the OHP-induced

elevation in brain ammonia occurred concurrently with the onset of convulsions.

They also noted a marked decrease in brain glutamine

( Gershen~vich

and Krichenskoya, 1954).

The bases for increased levels of ammonia during OHP are not known .
Enhanced catabolism of biogenic amin es in the brain (Faiman and Heble,

1966) may contr ibute some ammon ia to the ammonia pool.

Inhibition of the

citric acid cycle by OHP (s ee Dickens, 1962) may reduce the flow of
ammonia acceptors resulting in an increase in brain ammonia.

Increased

brain ammonia was repo ::- ted when the citric acid cycle was interrupted by
fluoroacetate poisoning
min~

(B enitez~

al., 1956).

forming enzyme , glutamine synthetase

Inhibition of the gluta-

( EC 6. 3 .1. 2), by methionine

sulfoximine has been shown to result in convulsions (Warren and Shenker,

1964).

These inve stigators and Folb e rgrova (196 4) reported that methio-

nine sulfoximine administration l ed to a marked and sustained decre ase
in cer ebral glut am ine and a corresp onding rise in ammonia levels.

This

may also be the case in the OllP- induc ed increase in brain ammonia since
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it has been shown that OHP inhibits glutamine synthetase (Gershenovich
~

al., 1963) .
In the CNS , the synthesis of glutamine exhibits priority over other

e nergy-consuming reactions and the synthesis of glutamic acid proceeds
in spite of the risk of a depletion of dicarboxylic acids , suggesting
t hat the brain must prevent intracellular accumulation of ammonia even
at a high cost (see Weil-Malherbe, 1962).
Ipro ni.:::izid has be en shown to decreas e the elevated ammonia levels
in th e blood of patients with severe hepatic damage (Pletscher

1960).

~

al. ,

Further, isoniazid, a structural analogue of iproniazid possess-

ing no MAO j_nhibitory activity, does not dec;:-ease the elevated ammonia
levels in the blood of these patients (Pletscher

~

al., 1960) nor does

it protect against OHP toxicity (Blenkarn ct al . , 1969).

From the preceding , it appears that theri is a relationship betwee11
e l evated ammonia levels and OHP convulsions .

Possibly, HAO inhibitors

may alleviate ORP toxicity by preventing this elevation .
SllCCINIC ACID
OHP has been shown to decrease the concentration of ATP in rat
l iver, kidney and brain

(Sanders~

al. , 1966) .

ATP is considered to be

t he primary source of chemical energy in brain tissue and is necessary
f or maintenance of electrical activity and the "sodium pump"
al ., 1968) .

(Kramer~

Consideration of these facts makes it apparent th a t the

decrease in brain ATP levels during OHP exposure may be important in the
etiology of OHP convulsions.

This decreas e in ATP may account for inhi-

bition of glutamine synthetase (Gershenovich et al. , 1963) referred to
in the previous section which considered ammonia involvement in OHP tox icity .
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The rationale for using succinic acid as a protective agent against
OHP convulsions lies in this agent's ability to provide reducing equivalents for the mitochondrial electron transport chain with subsequent
production of ATP .

Succinic acid prevented th e OHP-induced decrease in

cerebral ATP and decreas ed the incidence of OHP convulsions (Woodhall
~

al ., 1971) thus supporting the hypothesis that decreased ATP levels

are involved in the etiology of OHP seizures.
It is,
th em~elves

h o~ever ,

possible that th e decreased brain ATP l evels in

are no t responsible for OHP convulsions and that the actual

cause of the s eizure is a decrease in brain GABA an d/o r elevation in
brain ammoni2 l eve ls secondary to the ATP

d~crease.

For example, the previously mentioned OHP-induced decrease in
brain glutam.ine synthetase activity (Gershenovich

et:. -~ · ,

due to decreased ATP levels since this enzyme is ATP

1963) may b e

d e pende~t.

This

enzyme inhibition could then r es ult in the previously reported elevation ·
o f brain ammonia levels seen durH1g OHP exposure (Gershenovich and
Krich enskoya, J954; Sz am , 1969) .
Decreased GABA levels during OHP exposure are due to inhibition
o f GAD (Wood

~

al. , 196 7 ; Myles and Wood , 1968) and GAD is a Pyr P

requiring enzyme (Bax ter, 1970).

Since pyridoxal kin ase (EC 2 . 7. 1.35)

r equires ATP ( Baxter , 1970), the inhibition of GAD and consequent decrease
in brain GABA during OHP exposure could be due to inhibition of conversion of the Pyr P cofactor to its active form by pyridoxal kinase .
For this reason and since no one , to our knowledge, has investigated the effects of succinic acid on GABA or amm.onia metabolism, we
studied the effects of succinic acid on OHP toxic ity in relation to
GABA and ammonia metabolism .
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L-ASCORBIC ACID
In an attempt to reproduce the data of

Oliver~

al. (1970) which

showed that reserpine decreased the latency to OHP convulsions, it was
found that ascorbic acid markedly decreased the incidence of OHP convulsions.

A 20% solution of L-ascorbic acid had been used to dissolve

the reserpine base and it was found that the vehicle-treated mice were
protected against OHP seizures.
It has been shown that OHP exposure markedly decreased adrenal
gland ascorbic acid content (G erschman and Fenn , 1954) as did other
types of stre ss such as cold or hypoxia (Sayer and Sayer, 1949).

It

has also been demonstrated that ascorbic acid prot tcted 2eainst OHPinduced pulmonary damage but exhibited no protection against OHP convulsions (J amieson and Van Den Brenk, 1964).
We, th erefore , undertook to investigate the effect of ascorh5c
acid on OHP toxicity in r elation to GABA and ammonia metabolism in the
brain.
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III.

EXPERIMENTAL

ANIMALS
Swiss albino , random-bred male mice, weighing 25-35 g

(Charles

River Breeding Laboratories, Wilmington, Mass .) were used throughout
this study .

They were housed in animal

qua~ters

maintained at 21-23°C

with roor.1 lights alternated on a 12 h light-dark cycle.

Commercial

laboratory chow and water were available ad libitum up to one hour
before each experiment.

Animals were used not earlier than one week

after receipt from supplier via corrunercial shipper .
.MATERIALS
Analytical grade chemicals or equivalent were used
study .

througho ~t

the

Pargyline was supplied by Abbott Lab oratories , North Chicago , Ill.

Sodium succinic acid .h exahydrate was obtained from Cal- Biochem (Los
Angeles, Calif .) and L-ascorbic acid from Fisher Chemical Co. (Fairlawn ,
N. J.).

NADP was obta ined from P-L Biochemicals Inc., Milwaukee , Wisc .

and NADH from Cal-Bioch em .

GLDH ( ammonia-free) , GABase and glutaminase

(EC 3.5.1.2) were obtained from Worthington Biochemicals , Freehold ,
N. J.

L-glut ami c acid-l-C-14 (sp . act. 52 mCi / mM ) was obtain ed from

Cal-Atomic , Lo s Angeles , Calif.

The cyanomethemoglobin assay sy stem

was ob tained from Hycel Research Products, Houston , Texas .
phosphate was obtained from Cal-Biochem .
f rom New England Nuclear , Boston, Mass .
tions were made with deionized water .

Pyridoxal

Hyamine ( 10-X) was obtained
All reagents , buffers and dilu-
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HYPERBARIC OXYGEN CHAfIBER
The hyperbaric chamber (Figure 2) was designed by Van Tassel (1965)
and constructed with slight modification by the University of Rhode
Island Instrument Shop.

Modifications included stainless steel endplates,

an inch-thick plexiglass cylinder (t en in I.D.) two feet in length and an
elliptical door of one-inch-thick aluminum.

The chamber contained three

ft of 1/8 in copper tubing to allow circulation of water for maintenance
of a cons t an:: tempe r a ture (25 ± lcC).

Soda lime and calcium chloride were

placed in the bottom of the chamber to absorb carbon dioxide and moisture ,
resp e ctively .
EXPOSURE TO HYPERBARIC OXYGEN
Mice contained in individual plexiglass containers (3 x 3 x 3 in)
with perforated sides and tops to allow free circul a tion of
were placed in the OHP chamber.

c~1arr.ber

air ,

The chamber was flushed with 100%

oxygen (US P) for three min after which the chamber was compressed to
five atmospheres (60 psig) at the rate of 30 psig/min (t wo min).
comp ression was achieved in 15 min (thre e psig/min) .
the flow rate was maintained at three liters/min.

De-

During the studies

OHP exposures were

for a period of 90 min including flush, compression and decompression .
EXPERIMENTAL DESIGN
Mice were divided into four groups :

control (vehicle-treated) ,

drug (p argyline, L-ascorbic acid or succinic acid-treated), OHP exposed
plus vehicle-treated and OHP exposed plus drug-treated.
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PARAMETERS OF HYPERBARIC OXYGEN TOXICITY
Convulsions:

Time to onset of convulsion was measured as time to

onset of any convulsive movement .

Time to onset of a seizure-complex

was considered as time to onset of convulsions consisting of

t oni~

pos-

t ure , loss of righting reflex ( supine posture on side or back) or other
s eiz ure lasting 20 sec or more .
Pulmona ry damage :

After OHP exposure, both lungs were excised ,

weighed, placed in tar ed containers and dried to a constant weight at
75°C.

Values were reported as lung weights , as percent body weight

wet w.ei?J_lt x 100) and percent water ccntent of lungs
Clung
body we1ght
( lung wet weight - lung dry weight x lOO) .
1 ung wet weight

Lung hemoglobin was deter-

mined by the cyanomether.10globin method of Hainline (1958)_.
standard contained 80 mg cyanomethemoglob in/100 ml.

The Hycel

A preweighed vial

o f Hycel cyanomethemog lobin reagent was dissolved in water to make one
liter of solution.

Lungs were excised, weighed and homogenized in 25

volumes of ice-cold Hycel reagent .

Samples were centrifuged at 10 , 000

rpm ( Sorvall refrigerated centrifuge, rotor SS-34) for ten min as were
Hycel standards .

One ml of sup ernatant was mixed with two ml of reag ent

and read vs reagent at 540 mµ on a Beckm2n DB-G grating spectrophotometer .
Values were reported as hemog lobin content (mg) of both mouse lungs .
Lethality following hyperb ari c oxygen expos ure :

Mortality was

recorded at 30 min intervals for the first four hours after OHP exposure .

Mortality was then periodically record ed for up to 96 h after OHP

exposur e .
DRUG DOSAGE
Pargylin ~ ,

succinic acid and L-ascorbic acid we re administered
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in trape r itoneally at several doses and time intervals prior to OHP
exposure .

The dose and time tha t afforded maximal protection against

OHP convulsions was used in the pulmonary toxicity and mechanistic
studies.

All drugs were pre pared j ust prior to us e .

were made in saline and 10 ml / kg was administered .

Drug solutions
Drug solutions ad-

j usted to pH 6.5 with 2N NaOH or 211 HCl wer e also administered at the
dos e and time intervals affording maximal prot ecti on in order to determiri.e whether or not pH was a factor in the protective effect of any of
t he t hree drugs .
HEASURDIDlT OF GA.11'.·IA- Af1INOBUTYRIC ACID
The assay procedure was that of Graham and Aprison ( 1966 ).
were frozen in liquid nitrogen and kept at - 40°C for 20-24 h .

Hi c e

The heads

were then r emoved with an ice-cold hacksaw and cut longitudinally .
Whole brains were rapidly removed (45 sec), weighed and homogenized in
20 volumes of ice-cold 75 % (v /v) ethanol-.
fuged at 5,000 rpm at 0°C for 15 min .

Samp les were t hen cent r i-

The supernates were r emoved and

stor ed at 4°C while the pel let was resuspended in 20 volwnes of 75 %
e thanol and centrif uged as above .
combined and mixed thoroughly .

Both supernate fractions were the n

Two ml samples were added to s amp le

vi als and evaporated to dryness at 60°C in a water bath with constant
air flow into each vi a l.
time GABA was measured .
fiv e ml of water .

Samples were kept at - 40°C for

21~

h at which

The contents of each vial were suspended in

Two ml of s ample was shaken with an equal volume ·of

chlorofcrn and centrifuged in a clinic al c entrifuge ( International
Equipmen t Co .) at 3500 rpm for 20 min .
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The substrate solution 1 contained 1 . 4 ml pyrophosphate buffer
(0. 1 M, pH 8 . 4), 0 . 2 ml NADP (0 . 005 Min water) , 0 . 2 ml alpha-ketoglutaric
acid (O. l Min buffer) , 0 . 2 ml mercaptoethanol ( 0 . 06 M in buffer ) and
t en mg GABase enzyme .

Incubation mixtures contained 0 . 1 ml brain sample ,

st andard or water; 0. 1 ml pyrophosphate buffer and 0. 04 ml substrate
s ol ut ion.

Tissue blanks were prepared in the same manner except that no

GABase was added .
bolic shaker .

Incubations were for 45 min at 37°C in a Dubnoff meta-

After incubation, 0 . 2 ml a l kaline pho sphate 2 wa s added to

the tub es and mixed thoroughly .
t hen 0.2 ml of NaOH-H202

3

Tubes were heated at 60°C for 15 min,

was added , mixed thoroughly and the tubes were

heated at 60°C for ten min .

One ml of water was added to the tubes which

were then mixed thoroughly and the f l uorescence was read immed iately in
an Aminco-Bowman spectrophotofluorometer (excitation 360 mµ, emission
460 mµ , sensitivity setti~g at 50 and slit ·i6th of 1/64 in).

Value s

were reported as µmoles GABA/g bra in 0 Je t weight) .
MEASUREMENT OF G.l\MMA-Af1INOBUTYRIC ACID
TRANSANINASE ACTIVITY
The GABA-T assay procedure was that of Salvador and Albers (1959) .
Brains were removed rapidly with the aid of other investigators , weighed
1 Prepared

by disso l ving 4 . 46 g Na2P207-lOH20 in 80 ml water .
Norit-A was added and the solution stirred for 15 min after which t he
s olution was filtered through Celite . The pH was adjusted to 8 . 4 with
l N HCl and the vohnne adjusted to 100 ml. The buff e r was stored in an
amber bottle at 4°C and was prepared fresh 24 h prior to each assay .
2Prepared by dissolving 15 . 2 g Na3P04-12H20 and 2 . 68 g Na2HP04
i n sufficient water to make 100 ml. Solution was stored in an amber
bottle at rooffi temper at ure .
3Prepared fresh just prior to use by adding 0.2 ml 3% H20 2 to
t en ml 10 N NaOH .
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and homogenized in three volumes of ice-cold l.2S % Triton X-laa .
ml of GABA- a- KG 1 mixt ur e was added to a. 2 ml of homogenate .

a. s

ml samples of this mixture were added to

Five

One-half

ml of DAB reagent 2

(S a l ganicoff and DeRobertis , 196S) and stored on ice for us e as tissue
bl anks .

The r emoval of brains, weighing and homogenizat ion procedures

took no l onger than 4S min for 2a mice.
The succinic semialdehyde standard was prepared according to
Prescott and W&elsch (19 46 ).

Twenty mg ninhydrin was mixed with 1 . 4 ml

glutamir: acid folution (a.a a1 g/rril in
2.6 ml of
of

a.SN acetic

a.SN acetic

a.SN

acid was added .

acid and

2a

acetic acid) after which time

Reagent blanks contained four ml

mg ninhydrin.

Reagen t blanks and standards

were placed in boiling water for ten min .

After the tubes were cooled

in ice, the following r eagents were added at five min intervals:

a.4

ml guanidine carbonate (1 4Z in water ), one ml lead acetate (1 2% in water ,
prepared fresh each day) ,
were centrifuged at

a.S

ml of

SN

NaaH and a .l ml water .

Tub es

3,aaa

rpm for ten min in a clinical centrifuge .

a.s

ml aliquots of reagent blank and standard

After centr ifugation ,
were added to

a.s

ml of DAB re agent , mixed and stored on ice.

The GABA- a-KG mixture containing brain h omogenate was inc ubat ed
in a Dubnoff metabolic shaker und er ro om air at 37° C for 6a min.
incub ation ,

a.s

ml aliquots were added to

a.S

After

ml DAB reagent .

1 Prepared by dissolving

2.S7S g GABA and 1.46 g a -KG in sa ml
water . The pH was brought to 8 . 4 with SN NaOH and the volume adjust.ed
to laa ml with water . This mixture was prepared fresh daily and was
a.2S M in GABA and 0.1 Min a- KG .
2Prepared by dissolving 2.8
ml 1 H pot assium phosphate buffer
9 vol of 1 M KH2P04) . The pH was
justed to a final volume of sa ml

g 3,S-diaminobenzoic acid HCl i n 2S
(p H 5 . 9) (1 vol of 1 M K2HP04 plus
brought to S.9 with SN NaOH and adwith phosphate buffer .
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Samples , tissue blanks , reagent blanks and standards were heated
at 60 °C for 60 min .

Nine ml water was added to each tube and tubes were

centrifuged at 3 , 000 rpm for ten min.

Forty µl of supernatant was mixed

with ten ml water and samples were read in an Aminco-Bowman spectrophotofluor ometer ( excitation 405 mµ , emission 505 mµ, sensitivity setting at
50 and slit width of 1/64 in) .

Values were reported as µmoles succinic

s emialdehyde / g brain / h.
NEASURFJ•ii.N'T OF GLUTAHIC ACID DECARBOXYLASE ACTIVITY
The assay procedure was that of Roberts and Simonsen (1963) .

The

C-14-I.-gluta ui c: acid substrate solution was made by combining one ml of
l-C- 14-L-glutamic acid ( 25 microCi), 25 ml of 0.2 N L- glutamic acid
. adjusted to pH 6. 5 . with KOH , 10 ml of

5 ~~

(v/v) Triton X-100 , 36 ml of

0. 4 M potassium phosphate buffer 1 ( pH 6.5) and five mg pyridoxal phosphate .

This solution was adjusted to a final volume of 100 ml with 0 . 2M

potassium phosphate buffer 2 (pH 6 . 5) .

The solution was 5 x 10 -

in l-C-14 glutamat e (sp . act . 5 µc/mrnole), 2 x 10-

4

phate , 0 . 5% in Triton X-100 and 0 . 2 Min phosphate .

2

M

Min pyridoxal phosThe final pH was

6 . 5 and the mixture was stored in 25 ml portions at -40°C until use.
The procedure for collection of brain s amp les was as described in
t he GABA-T assay except that brains were homogenized in seven volumes
of i ce-cold deionized water .

One ml of homogenate was added to a

s cintillation vial that was us e d as an incubation fl a sk and one ml of

1 Prepared

by adding 0 . 4 H dibasic potassium phosphate to 0 . 4 M
monobasic pot ass ium phosphate until pH 6 . 5 was reached .
2Prepar ed by adding 0.2 M dib asic potassium phosphate to 0.2 M
monobasic potassium phosphate until a pH of 6 . 5 was reached .
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Hyamine ( 10-X) was added to another vial.

The unit 1 was assembled and

the homogenate s were preincubat ed at 37°C for ten min during which time
each flask was flushed with 100% nitrogen for two min .

The re act ion

was started by the addition of one ml cf substrate solution (warmed to
37°C) by means of a hypod ermic syringe.

The needles were immediately

r emoved to seal the unit and the samples were incubated at 37°C in a
Dubnoff metabo lic shaker.
At the end of exactly 15 min, 0 . 2 cc of 4N sulfuric acid was added
to stop t he reaction .

The units 'were allmv-ed to shake for another 60

min t o insure conplete absorption of the C-14-02 by Hyamine (10-X).
The counting vial was detached and ten ml of scintillation solution2
was added .

Radioactivity was counted in a Packard Tri-Carb liquid

scintillation spectrometer ( 25% gain setting) .
C-·lLf toluc.ne (New England nuc le ar )

~ :ere

det ermination of percent efficiency .

Internal standards of

added to every other sample for

All samples were counted for t en

Values were reported as µmoles C0 2 / g brain/h
(-s ample c pm - blank cpm x 32
GAD c atalyzes the conversion of one
p ercent efficiency x 110 ).

min.

mole of L- g lut amic acid to one mole of co2 and one mole of GABA .

1 The unit consisted of t wo counting vials connected by a g lass U

tube (1/ 4 i n I . D.). The vials and U tube were connected by means of 1/2
in lengths of high pressure tubing (soft rubber, 1/4 in I. D., 5/8 in O. D.).
Two needles (23 gauge, 1 in) per unit were ins erted through the tub~ng
and removed after addition of C-14 substrate . Sulfuric acid was introduced through the tubing by means of a needle and syringe at the end of
the incubation period. During pre-incubation and after nitrogen flush,
needles were stoppered with 1/8 in O. D. glass tubing sealed at both ends.
2Prepared by dissolving l g POPOP (1, 4-bis [ 2-(5-phenyloxazolyl)]
benz ene ) and 0.1 g PPO ( 2,5 diphenyloxazole ) in sufficient toluene t o
make one liter.
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MEASUREMENT OF BRAIN AMMONIA
Brain samples were collected as described in GABA methods except
that brains were homogenized in three volumes of ice-cold l N perchloric
acid.

Samples were centrifuged at 15,000 r pm for 15 min at 0°C.

One ml

of sup ernate was adjusted to pH 5 with 2N KOH and samples were again
centri fuged at 15,000 rpm for 15 min .

This supernatant was used for

de t ermination of ammonia and glutamine .
of Buttery and Roswell (1 971) .

The assay procedur e was tha t

The substrate solution was made by com-

binfog 27 ml glycerol , 0 . 85 ml GLDH (100 mg/5 ml) , 10 mg NADH , 0 . 121 g
c.-KG (dissolved in a small amount of buffer and adjusted to pH 7.8 with
l N NaOH).

The volwne of this solution was ad justed to 100 ml with pH

7.8 potassilllil phosphate buffer 1 (0.133 M).
This mi xt ure contained 8 .3 x 10-

3

Ma-KG , 0.1 M phosphate , 0.166

mg /I'll GLOR , 0. l mg / ml NADH and 0 . 34 g /rd glycer ol and was pH 7. 8.
This solution was pre-incubated at 37°C for 30 min in ord er to r emove
endogenous ammonia .

A 2.6 ml portion of th is pre-incubated mixture was

add ed to 0. 4 ml of brain extract and incubations were resumed at 37°C
for a fur t her 45 min .

Nonenzymic controls were run as follo ws :

0.4 ml

s apiples were incubated at 37°C for 45 min with 2.6 ml of a pre-incubated
mixture as describ ed but with GLDH replaced by buffer .

For each assay

ser ies enzymic and nonenz ymic reagent blanks were also incubated in
whic h 0.4 ml water replaced the ti ssue s amp le.
to prevent absorption of atmospheric ammonia .

All tubes were stoppered
Af ter the 45 min incuba-

tion period, six ml water was added to each tube, extinctions were
measured at 340 mµ in a Beckman DB-G spectrophotome ter and the ammonia
1 Prepared

by adding 0.133 M monobasic potassium phosphate to 0.133 M
dibasic: potassiu.rn phosphate until pH of 7. 8 was reached.
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content of each sample was calculated as follows :
Extinction, 340 mµ

Incubation
Enzymic , water
Enzymic, sample
Nonenz p ic , water
Nonenzymic , sample
Ammonia content of sample

=

A
B

c
D

(A - B) - ( C - D) x

1

6 .22

x 3 µmole

The calculation utilized the molar extinction co effi cient of NADH

(6 . 22 x 10 3 cm 2 ) and values were reported as µmoles amrnonia/g brain
(wet weigh r.) .

NEASUREMEt~T

or

B~IN

L-GLUTA)UdE

L-glutamine was measured by the method of Buttery and Roswell

(1971) .

Neasurer:;ents of glutamine utilized portions of the brain ex-

t racts prep ared for t:.1e ammonia assay so that both ammonia and glutamine
were sim ulta~eously measured in each brain.
Samples of brain extract (0.2 ml) were incubated at 37°C for 90 min
each with 0.4 ml of 0.1 1 citrate-phosphate buffer 1 , pH 4.9 , and 0.2 ml
glutaminase (2 mg/ml buffer).

A 0 . 4 ml portion of each incubation was

t hen added to 2.6 ml of pre-incubated enzymic ammonia assay mixture and
maintained at 37°C for 45 min, diluted with six ml water and read at

340 mµ .

This same procedure was follo we d in a control incubation with

O. 2 ml water r ep lacing the brain extract.

The initial ammonia content

o f each samp le was taken into account by including incubations containi ng 0. 2 ml brain extract or 0.2 ml water in which buffer replaced
glutaminase .

1 Prepared by adding 0 . 1 M citric acid to 0 . 2 M disodium phosphate
until a pH of 4 . 9 was reached (Mcllvaine, 1921) .
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The L-glutamine content of each sample was calculated as follows:

Initial incubation
Glutaminase , water
Glutaminase , sample
No glutaminase, water
No glutamin ase, sample

Extinction 340 mµ
after GLDH reaction

w
x
y

z

L-glut amine content of = (W _ X) _ (Y _ Z) x _2_ x 3 µmole
original 0.2 ml sample
6.22
Again the calculation utilized the molar extinction coefficient of
NADH.

Value s were rep orted as µmoles L-glutamine/g brain (wet weight) .

STATIS1ICAL HETHODS
The Stud ent "t" test for independent means and chi-square 2 x 2
contingency analysis (Dixon and Massey , 1969) were used to test for the
signific ance of differences between control and experimental groups .
Correlation coefficients were calculated using .linear regression analysis
(Dixon and Massey, 1969).

Tests were performed on an Olivetti Underwood

Programme 101 desk computer and th e level of significance was determined
by comparison of "t" and chi-square value s with values from standard
tables.
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IV .

RESULTS

PARGYLINE
Pilot studies were conducted to ascertain which pretreatment time
and dose of pargyline produced the l argest decrease in the incidence of
OHF convul.si(-r.s.

The resul ts of this preliminary study are founct in

Table l of the appendix.

The optimal effect in decreasing OHP convul-

s ions was provided by the intraperitoneal injection of 100 mg/kg pargyline 30 min prior to OHP exposure (appendix Table 1) .
OHP

co~vul sions

(Figure 3) .

was

significa~tly

The incidence o f

decreased by this dose of pargyline

Both the latency to convulsion onset and the latency to

seizure complex were prolonged by prior pargyline treatment (Fjgu re 3) .
Further , th e percentage of animals that had convulsed at the end of the
90 min OHP exposure was 40% and 20% for convulsion

onset and seizure

complex , respectively , in pargyline- treated mice, whereas all vehiclet reated mice had convulsed prior to the end of the OHP test period
( Figure 3) .

That this decreased incidence of OHP convulsions was net

due to the pH of the pargyline solution ( pH 3 . 8) is

sho1~1

by the fact

t hat a pargyline solution adjusted to a pH of 6 . 5 was as effective in
increasing the latency to OHP seizures and decreasing their incidence
a s was the more acidic pargyline solution (appendix Table 1) .
Pargyline aJso significantly decreased po s t-OHP mortality ( Figure
4) .

After OHP exposure , 90% of the control mice died within four has

opposed to a ten% mortality in the case of the pargyline-treated mice
(Figure 4) .
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EFFECT OF PARGYLIHE ON HYPERBAIUC OXYGEN CONVULSIONS .
0 - pargyline (100 mg/kg) , O - saline. Open symbols
denote significant difference from corresponding saline
value at the 0 . 05 level using chi- square test in groups
o f 26-30 mice .
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Figure 4 .
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\.•~~

EFFECT OF PARCYLINE ON LETHALITY FOLLOWI 1G HYPEREAr..IC
OXYGEN EXPOSURE .
()- pargyline (100 mg / kg) , 0 - saline.
Open symbols denote significant difference from corresponding saline value at the 0.0 5 level using the chi-square
test in groups of 26-30 mice .
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OHP significantly increased lung weight and lung water content
(Table 1).

Pargyline decreased these changes approx imat e ly to control

levels (Table i).

There was also significan tly l ess pulmonary hemo rrhage

in pargyl ine-treated mice as evidenced by th e fact that OHP exposure
elevated lung hemoglobin content by 98% in vehicle-treated mice as
opposed to only the 15% in crease seen in pa rgylin e-treated mice (Table
2).

Bra i n GABA levels were significantly decreased (35 %) after 90 min
of OHP exposure (Figure 5) .

(4 2%) in room

ai~ -expo sed

Pai;;g yline significantly elevated brain GABA

mice and prevented t he OHP-induced decrease

in brain GABA levels (Figure 5).

Since GABA leve ls Here highest 120

min after pargyline inj ec ti on ( Figure 5), th is time per i od was used for
th e dos e-res pons e curve (Figure 7).

Actual means , standard er ro rs,

levels of significance and percent chau3.es in brain GABA are shor,m in
Table 2 of th e appendix .

There was a signi f icant correlation between

brain GABA Jevels and the susceptibility of the indiv idual mice to OHP
convulsions i n that the v ehicl e-treated mice had l ower GABA l evels and
shorter lat encies to s eizures than did the pargyline-treated mice ( Figure

6).

The correl a tion coeffici ents were 0. 71 and 0.80 for l a t en cy to con-

vulsion ons e t and l atency to s e i z ur e comp l ex, r espec tively (Figure 6).
There was also a sign ifican t correlation (r
the dose of pargylin e
(Figure 7).

a~1inisteretl

= 0. 88 ,

p

<

0.0 005) between

and th e elevation in brain GABA l eve ls

The i ncrease in GABA was near- its maximllllt at 100 mg / kg

sinc e increas i ng th e dose of pargyline to 200 mg / kg produced only a
furth er seven percent elevation in brain GARA (Figure 7).

Ac tual means ,

standard errors , l eve l s of significance and percent changes in br ain
GABA ar e shown in Table 3 of th e appenciix .

Table 1.

EFFECT OF PARGYLINE ON HYPERBARIC OXYGEN-INDUCED ALTERATIONS IN LUNG WEIGHT AND
LUNG WATER CONTENT

Time (min)

Lung as %
Body We ight
1
(Mean ± S.E,)c

Saline

120

0 . 46 ± 0 . 014

Saline +
OHP (60 psig)

120
90

0 . 72 ± 0 . 065a

+5 7

81 ± 0 . 3a

+5

Pargyline

120

0 . 47 ± 0.016b

+2

76 ± 0 . 3b

-1

Pargyline +
OHP

120
90

0.50 ± O.Olla,b

+9

79 ±

'.l!"eatment

c

% Change

% Wa ter Conten~
(Mean ± S . E.)

% Change

e

77 ± 0 . 4

o. 4a , b

+3

aSignificantly different from saline controls at the 0 . 05 level using the Student " t" test.
bSignificantly different from saline+ OHP at the 0 . 05 level using the Student " t " test.
cPargyline (100 mg / kg) or saline (10 ml / kg body weight) was injected intraperitoneally .
dMean of six pairs of lungs .
ePercent change from saline controls .

Plus represents increase and minus, decrease.

w

'°

40

Table 2.

Treatment

EFFECT OF PARGYLINE ON HYPERBARIC OXYGEN-INDUCED
ALTERATIONS I N LUNG HEMOGLOBIN CONTENT

b

Time (min)

mg Hemoglobin/lung
(Mea n ± S . E .)
8 .5 5 ±

a

% Ch ange

e

a.so

Saline

120

Saline +
OHP (60 psig)c

120
90

Pargyline
(100 mg/kg )

120

8 . 39 ± 0.40d

Pargyline +
OHP

1 20
90

9. 85 ± 0 . 2Sc,d

16.97 ± 2 . 41

+98.5
-1.8

+15.3

~ach value represents the mean of five pairs of lungs .
bSaline or pargyline (10 ml /kg body weight) was injected intraperitoneally . Dose is given in parentheses .
cSi gnificantly different from saline controls at 0.05 l evel
(Studenl "t" test).
dSignificant l y different from saline + OHP at th e 0 . 05 level
(Stud ent "t" test) . ·
ePlus indicates increase and minus , decrease .
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ALTERATION OF HOUSE BRAIN GA1·01A-ANINOBUTYRIC ACID BY
PARGYLI NE AND HYPERBARIC OXYGEN . Percent change is
r epresen ted as mean ± S.E . Open symbols denote values
sien ifican tly different from controls at 0 . 05 level
using Stuclent "t" test . GABA concentration of control
animals is given in lJm oles/g brain as mean± S . E .
( )
repres en ts numb e r of mice used .
O- pargyline ( 100
mg/kg),
0 - saline + OHP (60 psig) .
pargyline +
OHP .
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CO VULSION 0 SET
a
D

D

r: 0.11
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Figure 6.

CORRELATION BETHEEN BRAIN GAHMA-AMINOBUTYRIC ACID AND
SUS CEPTIBILITY TO HYPERBARIC OXYGEN SEIZURES IN PARGYLINETREATED MICE.
0 - OHP , Cl - pa r gy line. The animals not
convulsing within 90 min were assigned an arbitrary convulsion l atency of 90 min . P value repres ents rejection
of the hypothesis that the correlation coefficient (r )
equals zero .
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Figure 7.

EFFECT OF VARIOUS DOSES OF PAHGYLINE O~ MOUSE BHAIN
GAMNA-Al!UmBUTYRIC ACID LEVELS. Pargyline was adminis tered 120 min prior to sacrifice. Each point repres ents the mean percent incre ase ± S.E. of duplicate
s &~ples.
Number in parentheses repres ents nunber of
animals used . Open symbo]s denote signific ant difference fro m controls at the 0 . 05 level using the Student
"t" t est . P value repr e sents rejection of the hypothesis
that th e correlation coefficient (r) equals zero .
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The activity of the GABA degrading enzyme , GABA-T, in mouse brain
was not altered by OHP exposure (Tables 3, 8 and 13).

Pargyline de-

creased GABA-T activity in the brains of mice exposed to room air at
no rmal atmospheric pressure and also in tho se of mice exposed to OHP ,
although the degree of inhibition was less in the pargyline-treated , OHPexposed mice (T able 3).

The inhibition of GABA- Tin pargy line-treated,

ro om air-exposed mice was not significantly different from that observed
in pargyline-treated mice exposed to OHP .
OHP exposure (90 min ) decreased the activity of th e GABA synthesizing enzyme , G.i\D, by about 20% (Tables 4, 9 and 14), and pargyline treatment did not significantly alter this OHP-induced decrease in
activity (Table 4) .

enz~oe

Pargyline treatment had no effect on brain GAD

act ivity in mice exposed t o room air (Table 4).
OHP exposure elevated brair; anmi.onia
glut amine levels (Tables 5, 10 and 15) .

L~veis

and decreased hraia

The maximal elevation in ammonia

(17 3%) occur red after 30 min of OHP exposure (Table 5) which was the
t ime at which most saline-treated mice began to demonstrate severe
convulsive activity (Figur0 3) .

The decreased glutamine levels, on the

other hand, were greatest after 60 min (37 %) and 90 min ( 36% ) of OHP
exposure (Tables 5, 10 and 15 ).

Pargyline had no effect on brain

anunonia or glutamine levels in mice exposed to room air (Table 5).
Pargyl ine treatment significantly lessened the elevation in brain
ammonia produced by OHP exposure and partially prevented the OHP-induced
decreas e in brain glutamine (Table 5) .
There was a significant correlation uetween brain arrnnonia levels
and the

susce~tibility

of the individual mice to OHP seizures after par-

gyline treatment (Figure 8).

The correlaticn coefficients were -0. 73 and
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Table 3.

ALTERATION OF HOUSE BRAIN GA.'-J}1A-AHINOBUTYRIC ACID TRANSAHINASE ACTIVITY BY PARGYLINE ND HYPF.RBARI C OXYGEN

Treatment
Dr ug-t
b ime
. a
OHP~timea

µmoles7'g brain/h
(Mean ± s . s . )f

Saline

-]20

0

229 ± 9 . 3

Saline

- 60

30

227 ± 3.0

>0 . 05

-3

Saline

-90

60

225 ± 2 .5

>0 . 05

-2

Saline

- 120

90

223 ± 3 . 2

>0.05

-1

Pargyline

-30

0

190 ± 6 . 1

<0 . 005

-17

Pargyline

-60

0

154 ± 9.5

<0 . 0005

-33

PargyJin e -120

0

171 ± _,c: . '-....

<0.0 005

-2 5

Pargyline

-60

30

196 ± 4 .5

<0 . 01

-15

Pargyline

- 90

60

186 ± 4 .0

<0.00 25

-19

Pargyline - 120

90

201 ± 4. ()

<0 . 01

- 13

~inutes.

bSalin e (1 0 ml/kg body we ight) or pargyl ine (100 mg / kg) was injecte~
intraperitoneally .
c

OHP exposure at 60 psig .

dStudent "t" test.
eµmoles succinic semial<lehyde .
f

Each value represents mean of five mice .

gMinus represents decrease .
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Table 4.

ALTERATION IN MOUSE BRAIN GLUTA.1'1IC ACID DECARBOXYLASE
ACTIVI TY BY PARGYLINE AND HYPERBARIC OXYGEN

Treatment
Drug-time
b . a
OHP<;_time a

µmoles C0 2 /g brain/h
(Mean ± S.E.)e

Saline

-120

0

Saline

-60

30

13. 7 ±

Saline

-90

60

Saline

-1 20

Pargyline
Pargyline

pd

% Change

f

16.3 ± 0.92

o. 70

<0 .05

-16

12 . 9 ± 0.47

<0.005

-21

90

12 . 8 ± 0.81

<0 .01

-22

-30

0

16 . 0 ± 0.88

>0 .05

-2

-60

0

15.7 ± 0.46

>0 . 05

-4

Pargyline -120

0

16.0 - 0. 76

>0.05

-2

Pargyline

-60

30

14 . 1 ± 1.10

>0.05

-13

Pargyline

-90

60

13.2 ±

<O . Oi25

--19

Pargyline -120

90

12 . 8 ± 0.85

<0.01

-21

o. 71

~inutes .
bSalin e (10 ml / kg body weight) or pargyline (100 mg/kg) was injected
intraperit oneally .
c
OHP exposure at 60 psig.
dStud ent "t" test.
e

Each value represents mean of five mice.

fMinus represents decrease.

47

Table 5.

EFFECT OF PARGYLINE ON HYPERBARIC OXYGEN-INDUCED ALTERATIONS
IN NOUSE BRAIN AHMONIA AND GLUTAMINE

Treatment

Drug~timea

OHP~timea

. b
Ammonia

0.31 8 ± 0.09

%

Change

Saline

- 60

0

Saline

- 60

30

Fargyline

- 60

0

Pargyline

-60

30

Saline

-90

0

0.3 38 ± 0.05

Saline

-90

60

0.81.0 ± 0.1 ·4

Pargy line

-90

0

Pargylin e

-90

60

Saline

-1 20

0

0.320 ± 0.09

Saline

-120

90

'J. 6 77 ± 0. 06 f

Pargyline -120

0

Pargyline -120

90

e

%
e
Change

Glut amineb
4.63 ± 0.12

0.8 68 .± 0.03f

+173

3. 74 ± 0.4l

-19

± o.o5g

-9

4. 72 ± 0.27g

+2

0 . 472 ± 0.07g

+48

4.86 ± 0.25"'"

+s

o. 2s9

0.30 9

T

4 . 1L1 ± 0.25
J:

f

O.Olfg

2.60 ± 0.321.

-37

-9

3.81 ± o . 1s 8

-8

+46

3.95 ± 0 . 15g

-5

L, .

68 ± 0. 20
f

+112

3.01 ± o.30·-

-36

+7

4.82 ± 0.17g

+3

0.48 4 ± 0.94g

+51

3.68 ± 0.32f ,g -21

~linutes.

b~moles/g brain

i

S.E.

Mean of five mice.

cSalin e (10 ml/kg body weight) or pargyline (100 mg / kg ) was inject ed
intrap eritoneally .
d

e

OHP exposure at 60 psig.
Percent change compared to saline controls.
and minus, decrease .

Plus represents

in~r ease

fSi gnificantly different from saline controls at the 0.05 level (St udent
"t" test).
gSignifi cantly different from saline+ OHP at the 0.0 5 l evel (Student
"t" te st) .

48

CONVULSION ONSET

•

1.2 5

r=

-0.13

P<0.0 005

'· 0
0.1 5

z

0. 50.

n::
c.o

0.25

(.!)

.......
(f)

w
-'
0

-

0
SEI ZURE CO MPLEX

•

1.2 5

=t

r ::.o.ao
p < 0,000 5

1.0

<(

z

0.75

0

~

D

0.50

f)

<(

0.25
0
0

Figure 8.

30
60
LATENCY {M IN)

90

CORRELATION BETi-IEEN BRAIN AHHONIA AND SUSCEPTIDILITY TO
HYPERBARIC OXYGEN SEIZURES IN PARGYLINE-TREATED MICE .
- OHP , 0 - pargy line . The an i mals not convulsing wi thin
90 min ~ere assigned an arbitrary conv ulsion latency of 90
min. P value repres en ts rejection of t he hypothesis that
the cor~ ela tion coeffic i ent (r ) equals zero .
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-0.80 for convulsion onset and seizure complex, respectively (Figure 8).
The correlation between decreased levels of glutamine and OHP seizure
susceptibility (r = 0 . 21) was not significant in the case of latency to
convulsion onset.

0.65, p

<

There was, however ,

2

significant correlation

~r =

0.01) between decreased glutamine levels and seizure suscepti-

bility in the case of seizure complex (Figure 9).

SUCCINIC ACID
Prelimina r y studies showed that the intraperitoneal injection of

12 mmoles/kg (l. 39 g/kg) succinic acid 60 min prior to OHP exposure
d _creasecl the incidence of OHP convulsions more than did other doses g1ven
at oth er time intervals (appendix Table 4).

Both the latency to convuJ-

sion onset and the latency to seizure complex were prolonged by prior
succinic acid tr eatment (Figure 10).

The

perc~ntage

of anirr:als that had

convulsed at t he end of the 90 min OHP exposure was approximately 60%
and 40% for convulsion onset and seizure complex , respectively, in
succinic acid-treated mice , whereas all saline-treated mice had convulsed
prior to the end of the OHP test period (Figure 10).

As in the case of

pargy line , the decreased incidence of OHP seizures after succinic acid
treatment was not due to the pH of the drug solution (pH 7.9) since a
succinic acid solution adjusted to pH 6.5 was as effective as the more
basic

solution in decreasing the incidence of OHP seizures (appendix

Table 4).
Succinic acid significantly decreased post-OHP mortality (Figure
11).

After OHP exposure, 85% of the saline-treated mice died within 4 h

as oppos ed to only 20% in the case of succinic acid-treated mice (Figure
11).
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Figure 9 .

CORRELATION BETWEEN BRAIN GLUTAHINE AND SUSCEPTIBILITY TO
HYPERBARIC OXYGEN SEIZURES IN PARGYLINE-TREATED MICE .
0- pargyline (100 mg /kg ). The animals
- OHP ( 60 psig),
not convclsing within 90 min were assigned an arbitrary convulsion latency of 90 min . P value represents rejection of
the hypoth~sis that the correlation coefficient (r) equals
zero.
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EFFECT OF SUC:CINIC ACID ON HYP ERBARIC OXYGEN CONVULSIONS .
0- succinic acid (12 mmoles / kg) , 0 - saline . Open symbols denote significant difference from corresponding
saline value at the 0 . 05 level using chi-square test in
groups of 18-20 mice.
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Figur e 11.

EFFECT OF SUCCINIC ACID ON LETHALITY FOLLOWING HYPERBARIC
OXYGEN EXPOSURE .
()- succinic acid (12 mmoles / kg ), O s a line . Open symbols denote significant difference from
corresponding saline value a t t he 0.05 l eve l using chisquare t est in groups of 18-20 mi ce .

Table 6.

EFFECT OF SUCCINIC ACID ON HYPERBARIC OXYGEN-INDUCED ALTERATIONS IN LUNG
WEIGHT AND LUNG WATER CONTENT

Treatmentc

Time (min)

Lung as %
Body Weight d
(Mean ± S. E. )

% Change

e

% Water Content
(Mean± S.E .) d

% Change

e

·-

Saline

150

0.52 ± 0.014

---

74 ± 0.6

Saline +
OHP (60 psig)

150
90

0.81 ± 0.047a

+56

78 ± l.Oa

+6

Succinic acid

150

0.49 ± 0.008b

-6

74 ± 0.2b

0

Succinic acid +
OHP

150
90

0.61 ± 0.047b

+17

74 ± 0.7b

0

aSignificantly different from saline contrc:ls at the 0.05 level using the Student "t" test.
bSignificantly different from saline + OHP at the 0.05 level using the Student "t" test.
cSuccinic acid (12 mmoles/kg) or saline (10 ml/kg body weight) was injected intraperitoneally.

~ean of five pairs of lungs.
ePercent change from saline controls.

Plus indicates incr ease .

V1

w
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Succinic acid treatment significantly de creased the OHP-induced
increase in lung weight and lung water content (Table 6) .

There was

also significantly less pulmonary hemorrh age in succinic acid-treated
mice as evidenced by the fact that OHP expo sure elevated lung hemoglobin
content by 98% as opposed to the 15% increase seen in the succinic acidt reated mice (Table 7) .
Brain GABA levels were significantly decrease::l (35 %) at th e end of
the OHP t est period (Figures 12 and 19).

GABA levels we re elevated by

abou t 20% 150 r-1in after succin ic acid injection (Figure 12).

The maxi-

mal elevation i n GABA levels was seen at 90 min after succinic acid
treatment (Figure 12), and this time period was used in the doseresponse curve (Figure 14).

After 30 min of OHP exposure, GABA levels

were sti.11 elevated by 20% in the s·uccinic acid-treated mice but this
level decreased to that of saline-·treated; room air-exposed mice at the
end of 90 min of OHP exposure (Figure 12).

Actual means, standard

errors , levels of significance and percent changes in GABA levels are
s hown in Table 5 of the appendix.

There was a significant correlation

b etween brain GABA levels and the susceptibility of the individua l mice
t o OHP convulsions in succinic acid-treated mice (Figure 13) .

The cor-

r elation coefficients were 0 . 56 and 0 . 77 for latency to convulsion ons et
and latency to seizure comp lex, respectively (Figure 13) .

There was

a lso a significant correlation between the dose of succinic acid admini stered and the degree to which brain GABA was elevated (r
p < 0 .0005) (Figure 14).

=

0 . 86,

Although th e highest dose of succinic acid

( 24 mmoles/kg ) el e vated GABA leve ls by 60%, one of the five mice di e d
before sacri f ice
, an0 the remaining four mice appeared sick (Figure 14) .
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Table 7.

EFFECT OF SUCCINIC ACID ON HYPERBARIC OXYGEN-INDUCED
ALTERATIONS IN LUNG HEMOGLOBIN CONTENT

Treatment

Time (min)

mg Hemoglobin /lung
(Ne an ± S. E.)
8.55 ±

a

% Change

e

a.so

Saline

150

Saline +
OHP (60 psig)

150
90

16 . 97 ± 2.4lc

+98.5

Succinic acid
(1 2 mmoles/kg)

150

8.17 ± 0.44d

-4.5

Succinic acid +
OHP

150
90

9.87 ± 0.56

. +15.4

aEach value repres ents the mean of five pai rs of lungs.
bSaline or succinic acid (10 ml/kg body weight) was injected
intrap eritoneally . Dose is given in pa r enthes es .
cSignif icantly different from saline controls at the 0.05 level
( Student "t" test) .
dSignificantly different from saline+ OHP at the 0 . 05 level
( Student "t" test).
ePlus represents increase and minus , decrease .

56

1
... .
......
.'·.....
. ..
·.·
•.:·:........
.
.
...
.
•"'
:--:·...
.:.:.:.:.:.:.:.·.•·..•·.....
................·... ••.•.
.'. :I .__.;............
'.;;:. :.:::::::::::::::.:•:::::
..:::..:,::..:::..:::..:::..:::..:::..:::..:::..=::::::::.;.
..:.....
:.: . . ... ..:.:.:.:.:....:.:.:.:.
·.·.·.·.·.··:·:·. "':.·.·.·:·:·:·:·:·:
.. . . ..
• •

• •

•

•

• '*\ • • •
•

• .)

'I • • •
~

"' ?

•

'

•: (.;.~: .,

,.

'"~ .,

..... ..,
---·~ .~-. ...:.. : - . .

()

©

...·.·" ...

···.·=··=

·-·~-.:~~-:-::

..... . :· ,>·.·.·:·:·:·:·:·:·:·:·:·:·:··-·.·.·.·;·;·;·J
..
:-:·:·:•:•:t\
·.·.·.·.•.(
·.·.·.·.·.·.·.·.·.·.·.-·.·.·.·.·.·.·.·.'1
....
...- ,-·......................................
,..,,.

·~·
~· :.:.: . :. : ~:': .;. --- · !~ ••••••• :.:.:.:.:.:.:.: ••••••• ••••• ~

::::::::::::::::::::::::::=~:·~:f.·.:::::::::::::
:;::::::::j
. ................ •l

... ....................... ( . .

.·.·.·.·.·.·.·:·:·:··.·.·.·.·.·."-·j··.·.·.·.·:-.
). ~. .. ,,
..........·.·.•.• .•.•.•
.·.·.·.·.·.·.·· · · · · · · -- .

• •• • -.....::. •• ,.--

•• j

·.·.·.·.·.·.·. · ~-;

-:-~

I

Figure 12 .

ALTERATION OF MOUSE BRAIN GAMMA-AHINOBUTYRIC AC ID BY
SUCCINIC ACID AND HYPERBARIC OXYGEN . Percent change is
r epresented as mean ± S. E . Opea symbols d e no t e values
s ign i ficantly different from controls at 0.05 level using
St ud e nt "t" test. GABA con centration of control animals
i s giv en in µmoles/g brain as mean ± S. E . Shaded area
d enot e s OHP exposure .
( ) represents numb e r of mice used .
0 - succinic acid ( 12 mmo les/kg ), O - saline + OHP ( 60
p sig) , ~
succinic acid + OHP .
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CORRELATION BETWEEN BRAIN GPJ11-'1A-ANINOBUTYRIC ACID AND
SUSCEPTIBILITY TO HYPERBARIC 01.'YGEN SEIZURES IN SUCCINIC
ACID-TREATED MICE . 0 - OHP, 0 - succinic acid. The
animals not convulsinr; within 90 min were assigned an
arbitrary convulsion latency of 90 min . P value represents rejection of the hypothesis that the correlation
coefficient (r) equals zero .
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CORRELATION BETWEEN DOSE OF SUCCINIC ACID AND BRAIN GANHAAHINOBUTYRIC ACID LEVEL. Succinic acid was administered
90 min prior to sacrifice. Open symb ols deno te signifi.cant
diffe rence from saline controls at the 0.05 level (Stud en t
"t" test). P value represents rejection of the hypothesis
that the correlation ccefficient (r) equa ls zero. At the
highest dose, 1/5 rr.ice died and the remainjng mice appeared
sick.
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Actual means, st andard errors, levels of signif icance and percent changes
in GABA levels are shown in Table 6 of the appendix.
GABA-T activity was significantly increased (15 %) 150 min after
succinic acid trea tment ; however, the GABA-T activity of succinic acidtreated mice exposed to OHP was not significantly different from that of
saline-treated , ro om air-exposed animals (Table 8).
GAD activity was also increased (45 %) 150 min after succinic acid
treatment (Table 9) .

There was no OHP-induced decrease in GAD activity

in succinic acid-treated mice (Tabl e 9); in fact, GAD activity was significantly increased (23%) in succinic acid-treated mice after 30 min
of OHP ex posure.
after 90

This increase in GAD ac tivity was reduced to about 10%

min of OHP exposure (Table 9) .

The OHP-induced increase in brain anurtonia levels was significantly
less in succinic acid-treated mice than in saline-treated mice, and
succinic acid-treated mice did not exhibit significantly greater

a~monia

l evels than did saline-treated , room air-exposed animals (Table 10).
The OHP-induced decrease in brain glutamine l evels was also significantly
less in succinic acid-treated mice (Table 10) .

Glutamine l evels were

not significantly decreased in succinic acid-treated, OHP-exposed mic e
when compared to saline-treated, room air-ex posed controls (Table 10).
As in the case of pargyline , there was a significant correlation between
elevation in brain ammonia levels and the susceptibility of the individual mice to OHP seizures in succinic acid-tr eated mice (Figure 15).
The correlation coefficients were -0.76 and -0.81 for l atency to convulsion onse t and latency to seizure complex , respectively (Figure 15).
The corr elation between decreased glut amine levels and OHP seizure susc eptibility (r

0.27) was not significant in the case of convulsion
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Table 8.

ALTERATION OF HOUSE BRAIN GAMHA-Af1INOBUTYRIC ACID TRA~·TS AMINASE ACTIVITY BY SUCCI HC ACID AND HYPERBARIC OXYGE N

Treatment
Drug-time
b . a
OHP<:..timea

e
µmole s /g brainfh
(Mean ± S. E. )

pd

% Changeg

Saline

-150

0

224 ± 3.6

Saline

-90

30

227 ± 3 . 0

>O. 05

+l

Saline

-120

60

225 ± 2 . 5

>0.05

0

Saline

-150

90

223 ± 3 . 3

> o. 05

0

Succini c
acid

-60

0

24 7 ±. 5.3

<O . 01

+10

Succinic
acid

-90

0

262 ± 7. 6

< 0. 005

+17

Suc cinic
acid

-150

0

258 ± 7 . 6

<0 . 005

+15

Succinic
acid

- 90

30

220 ± 4.4

> o. 05

0

Succinic
acid

-120

60

224 ± 3 . 0

> 0 . 05

0

Succinic
acid

-150

90

223 ± 3 . 3

> o. 05

0

C\1inutes .
bSaline (10 ml/kg body weight) or succinic acid (12 mmoles/kg) was
injected intraperitoneally .
c
OHP exposure at 60 psig.
d

Stud en t "t" test.

eµmoles succinic semiald ehyde .
f

Each value repres en ts mean of five mice .

8 Plus r epresen ts increas e .
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Table 9.

ALTERATION OF MOUSE BRAIN GLUT.AJHC ACID DECARBOXYLASE
ACTIVITY BY SUCCINIC ACID AND HYPERBARIC OXYGEN

Treatment
a
OHF-timea
Drug-time
b

.

µmoles C02/g brain/h
(Mean ± S. E. ) e

% Change

Saline

-150

0

15.5 ± 0.56

Saline

-90

30

13.7 ± 0. 70

<0 . 05

-12

Saline

-120

60

12.9 ± 0.47

<0 .0025

-17

Saline

-150

90

12.8 ± 0.81

<0.0125

-18

Succinic
acid

-60

0

18.2 ± 0.84

<0 .01

+17

Succinic
acid

-90

0

21.2 ± 0.88

<0.0005

+37

Succinic
acid

-150

0

22.5 ± 0.03

<0 .0005

+45

Succinic
acid

-90

30

19.1 ± 0.82

<0 .00 25

+23

Succinic
acid

-120

60

17.0 ± 0.57

<0.05

+9

Succinic
acid

-150

90

16.9 ± 0.80

>0.05

+9

~inules.

bSaline (10 ml/kg body weight) or succinic acid (12 mmoles/kg) ~-1as
injected intraperitoneally.
c
OHP exposure at 60 psig.
dStudent "t" test.
e
Each value represents mean of five mice.
f

Plus represents incr ease and minus, decrease .

f
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Table 10.

EFFECT OF SUCCINIC ACID ON HYPERBARIC OXYGEN-INDUCED
ALTERATIONS IN HOUSE BRAIN AMMONIA AND GLUTAI1INE

Treatment
c . a
orrf-timea
Drug-time

. b
Amrn onia

%
e
Change

%
e
Change

Glutamineb
4.63 ± 0.12

Saline

-90

0

0.32 ± 0.09

Saline

-90

30

0.87 ± 0.03£

+173

Succinic
acid

-90

0

0.31 ± 0.06g

-3

Succini.c
acid

-90

30

0.4 4 ± 0 . 07g

+37

Saline

-120

0

Saline

-120

60

0.81 ± 0.14£

+140

2.60 ± 0.32£

-3 7

Succinic
acid

-1 20

0

0.34 ± 0.03g

0

3.88 ± 0.15g

-6

Succinic
acid

-1 20

60

0.50 ± 0.07g

+48

3. 88 ± 0.22 °

Saline

-150

0

0.32 ± 0.09

Saline

-150

90

0.68 ± 0.06£

+112

3.01 ± 0.17£

-36

Succinic
acid

-150

0

0.40 ± 0.07g

+25

4.69 ± 0.24g

0

Succinic
acid

-150

90

0.42 ± 0.04g

+31

3.74 ± 0.24g

-2 0

0.34

i:

0.05

3.74 ± 0.43£

-19

4.55 ± 0.15

-2

4 .7 4 ± 0 . 15g

+?

4.14 ± 0.25

0-

-6

4.68 ± 0.20

'\1inutes.
b

µmoles/g brain ± S.E.

Mean of five mice.

cSaline (10 ml/ 1.<g body weight) or succinic acid (12 mmoles/kg) was
inject ed intraperitoneally.
d

e

OHP exposure was at 60 psig.
Percent change compared to saline controls.
and minus, decre ase .

Plus represents increase

£Signific antly different from saline controls at the 0.05 level (Student
"t" tes t) .
gSignifi cantly different from saline + OHP at th e O. 05 level (Student
"t" test).
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Figure 15 .

CORRELATION BETHEEN BRAIN .1UMONIA AND SUSCEPTIBILITY TO
HYPERBARIC OXYGEN SEIZURES IN SUCCINIC ACID-TREATED MICE .
- succinic acid (12 mmoles/kg, IP).
o - OHP (60 psig),
The animals not convulsing within 90 min were assigned an
arbitr ary convulsion lat ency of 90 min . P value represents
rejection of the hypothesis that the correlation coeffic ient (r) equals zero .
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onset.

There was a significant correlation between glutamine levels and

seizure susceptibility (r

=

0.66, p < 0.005) in the case of the seizure

complex (Figure 16).
L-ASCORBIC ACID
Preliminary studies (appendix Table 7) showed that the intraperitoneal injection of 12 mmoles/kg (2.11 g/kg) of L-ascorbic acid 60 min
prio r to OHP exposure decreased the incidence of OHP convulsions more
than did other dose s given at oth er time intervals (app end ix Tab l e 7).
1-ascorbic ac id significantly decreased the incidence of OHP convulsions
and significan tly increased t h e latency to OHP seizures when compared
to saline-treated mice (Figure 17).

In the case of convulsion onset

and seizure complex, approx imately 20% of the ascorbic acid-treated mice
had convulsed at the end of the OilP test period as opposed to 100% of
the saline-treated animals (Figure 17).

The decreased incidence of

OHP seizures after ascorbic acid treatmen t was not due to the pH of the
drug solution (pH 2 .5) since an ascorbic acid solution adjusted to pH
6.5 was as effective as the more acidic solution in de creasing the incidence of OHP convulsions (appendix Table 7).
Ascorbic acid-treated mice demonstrated sjgnificantly less postOHP mortality than did saline-treated mice for up to 12 h after OHP
exposure (Figure 18).

At the end of 72 h, however, post-OHP mortality

was about 90% in both groups of mice ( Figure 18).
Ascorbic acid treatment significantly decreased the OHP-induced
increase in lung weight when comp ared to saline-treated mice (Table 11).
In spite of as corbic acid treatment , however , lung weights were significantly higher than those of saline- trea t ed or ascorbic acid-treated,
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CORRELATION BETWEEN BRAIN GLUTAHINE AND SUSCEPTIBILITY TO
HYPERBARIC OXYGEN SEIZURES IN SUCCINIC ACID-TREATED MICE.
O - OHP (60 psig) , O - succinic acid (12 nunoles / kg ).
The
animals not convulsing within 90 min were assigned an arbit rary convulsion latency of 90 min . P value represents rej ec tion of the hypothesis t hat t he correla tion coefficient
(r) equals zero .

66

CO NVULSION ONSET

100

80

60
40

20
0

w

~

0
SE IZ URE

::> 100

>
z
0

80

~

60

u

-0-0

()

40
20

~

0
0

30

60

90

0 H p ( Ml N)

F igure 17.
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EFFECT OF L- ASCORBIC ACID ON LETHALITY FOLLOHING HYP ERBARIC
0- ascorbic ac i d ( 12 mmoles/kg) , 0 OXYGEN EXPOSURE .
s aline . Open symbols denote significant difference from
co rresponding saline v a lue at the 0. 05 l evel using chisquare test in groups of 18-19 mice .

Table 11.

EFFECT OF L-ASCORBIC ACID ON HYPERBARIC OXYGEN-INDUCED ALTERATIONS IN LUNG
WEIGHT AND LUNG WATER CONTENT

Time (min)

Lung as %
Body Weight d
(Mean ± S . E. )

% Change

Saline

150

0.52 ± 0.014

---

74 ± 0.5

Saline +
OHP (60 psig)

150
90

0.81 ± 0.047a

+56

78 ± 1.0a

+6

Ascorbic acid

150

0.53 ± 0.022b

+2

71 ± o.5b

-4

Ascorbic acid +
OHP

150
90

0.67 ± 0.044a,b

+29

78 ± 1. 9a

+6

Treatmentc

e

% Water Content
(Nean ± S. E.) d

% Change e

aSignificantly different from saline controls at the 0.05 level using the Student ''t'' test.
bSignificantly different from saline + OHP at the 0.05 level using the Student ''t'' test.
CL-ascorbic acid (12 mmoles/kg) or saline (10 ml/kg body weight) was injected intraperitoneally.
<\iean of five pairs of lungs .
ePercent change from saline controls.

Plus represents increase and minus, decrease.

°'
00
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room air-exposed mice (T able 11) .

Ascorbic acid treatment had no signi-

ficant effect on th e OHP-induced increase in lung water content (Table
11).

Ascorbic acid-treated mice exhibited less pulmonary hemo rrh ag e

after OHP exposure when compared to saline-treated mice (Table 12).
There was still, howeve r, a 34% increase in lung hemoglobin in the ascorbic acid-tr eated mice (Table 12) as opposed to only a 15% increase in
lung hemoglobin seen after pargyline (Table 2) or succinic acid treatment (Table 7) .
Ascorbic acid treatment had no effect on brain GABA levels in
room air- exposed mice nor did it preve nt the OHP-induced decrease in
brain GABA levels (Figure 19).

Actual means, standard errors, levels

of signific ance and pc:cent changes in brain GABA levels are shmm in
Table 8 of the append:.x.

Further , th ere was no significant correlation

between brajn GA3A

and individu:i.: susceptibility of the mice to

OHP seizures.

leve~s

The correlation coefficients for latency to convulsion

onset and latency to seizure complex were 0.23 and 0.27 , respectively .
Ascorbic acid t reatment had no effect on GABA-T activity in OHPor room air-exposed mice (Table 13).

Also , ascorbic acid treatment had

no effect on GAD activity in room air-exposed mice nor did it prevent
the OHP-induced decrease in GAD activity (Tab l e 14).
The OHP-induced increase in brain ammonia levels was significantly
less in ascorbic acid-treated mice, and ascorbic acid-treated mice demonstr ated no significant increase (35 %) in brain ammonia levels when
compar ed to saline-treated, room air-exposed animals (Table 15).

The

" amine was also significantly less in
OHP-induced d e creas e in brain glut
ascorbic acid-treated

~ice

(Table 15).

There was no signific an t decre a se

in brain glutamine in ascorbic aci.d-treated mice after 30 or 60 min of
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Table 12.

Treatment

EFFECT OF L- ASCORBIC ACID ON HYPERBARIC OXYGENINDUCED ALTERATIONS IN LUNG HEMOGLOBIN CONTENT

b

Time (min)

mg Hemoglobin/lung
(Mean ± S. E.)

a

% Change e

Saline

150

8.55 ± 0.45

Saline+
OHP (60 psig)

150
90

16.95 ± 2.4lc

+98 .5

Ascorbic acid
(1 2 mmoles/kg)

150

8.93 ± 0.25d

+4 . 4

As corbic acid +
OHP

150
90

11. 49 ± 0.45c

+34.4

aEach value repr esents mean of five pairs ·of lungs .
bS aline or ascorbic acid (10 ml/kg body weight ) was injected
i ntraperitoneally . Dose is given in parentheses .
cSigni ficantly different from saline controls at the 0.05 level
(S tudent "t" t est ).
dSignific antly different from saline controls at the 0.05 level
(S tudent "t" t est ).
ePlus represents increase.
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Figure 19.

ALTERATION OF HOUSE BRAIN GAf:!HA-AHINOBUTYRIC ACID BY
L-AS CORBIC ACID AND HYPERBARIC OXYGEN . Percent change
is r epresented as mean ± S . E. Open symbols denote ·value s
s ignificantly different fro m controls at 0.05 leve l using
St udent "t" test. GABA concentra tion of control animals
is given in µm oles/g brain as mean ± S.E. ( ) r epres ents numb er of mice used . O - ascorbic acid (12
mmolcs / kg ), 0 - s a lin ~ + OHP ( 60 psig ),
~ - ascorbic
acid + OHP . Shad ed area represents OHP exposure .
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Table 13.

ALTERATION OF MOUSE BRAIN GAMMA- AMINOBUTYRIC ACID
TRANSAMINASE ACTIVITY BY L-ASCORBIC ACID
AND HYPERBAR IC OXYGEN

Treatment
Drug-time
b . a

OHP'=-timea

e
µmoles/g brain/h
(Mean - S. E.) f
.J..

p

d

% Changeg

Saline

-150

0

224 ± 3.6

Saline

-90

30

227 ± 3.0

>0.05

+l

Saline

-120

60

225 ± 2.5

>0.05

0

Saline

-1 50

90

223 ± 3.3

>0.05

0

Ascorbic
acid

-60

0

226 ± 4.3

>0.05

+l

Ascorbic
acid

-90

0

223 ± 1. 3

>0.05

-1

Ascorbic
acid

-150

0

226 ± 3.7

>0.05

+l

Ascorbic
acid

-90

30

223

3.5

>0.05

-1

Ascorbic
acid

-120

60

223 ± 2.8

>0.05

-1

Ascorbic
acid

-150

90

222 ± 3.4

>0.05

-1

:!

C\1inutes.
bSaline (10 ml/kg body weight) or ascorbic acid (12 mmoles / kg)
was injected intraperitoneally .
c
OHP exposure at 60 psig.
d
Student 11 t II test.
e
µmoles succinic semialdehyde.
f
Each value represents mean of five mice.
gPlus represents increase and minus, decrease.
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Table 14.

ALTERATION OF MOUSE BRAIN GLUTAdIC ACID DECARBOXYLASE
ACTIVITY BY L-ASCORBIC ACID AND HYPERBARIC OXYGEN

Treatmen t
OHPc
. a
b . a
-time
Drug-time

µmoles C02/g brain/h
(Mean± S.E.) e

% Chang e f

Saline

-120

0

15. 6 ± 0. 80

Saline

-90

30

13.7 ± 0.70

>0.05

-12

Saline

-120

60

12.9 ± 0.47

<0.01

-18

Sal ine

-150

90

12.8 ± 0. 81

<0.025

-18

Ascorbic
acid

-60

0

15.9 ± 0.66

>0.05

+2

Ascorbic
ac i d

-90

0

15.4 ± 0.53

>0.05

-1

-150

0

15.9 ± 0.36

>0.05

+l

Ascorbic
acid

-90

30

13. 7 ± 1.10

>0.05

-12

Ascorbic
acid

-120

60

12.1 ± 0.91

<0.0125

-23

Ascorbic
acid

-150

90

12.8 ± 0.87

<0.025

-18

l~. scorbic

a c id

8Minutes.
bSaline (10 ml/kg body weight) or L-as corbic ac id (12 mmoles /kg) was
injected in traperitoneally.
c
OHP exposure at 60 psig.
dStudent "t" test.
eEach value represents mean of five mice .
f

Plus repres ents in crease and minus, decrease.
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Table 15.

EFFECT OF L-ASCORBIC ACID ON HYPERBARIC OXYGEN-INDUC ED
ALTERAT IONS IN MOUSE BRAIN ANHONIA A~m GLUTAHINE

Treatment
c

.

Drug-time

a

_a

•

08 ~-time

. b
Amm onia

a

%
Change

Glutamineb

%
e
Change

Saline

- 90

0

Saline

-90

30

0. 87 ± 0 . 03f

+173

Ascorbic
acid

-90

0

0.38 ± 0 . 06g

+18

4 . 72 ±

Asc:orb.:.c
acid

-90

30

0 . 43 ± 0.04g

+36

Saline

-120

0

Saline

-1 20

60

0 . 81 ± 0 . 14f

+140

2.60 ± 0 . 32f

-37

Ascorbic
-120
acid

0

o . 38 ± o.osg

+11

4 . 16 ± 0 . 29g

0

Ascorbic
-120
a c id

60

0 . 47 ± 0.07g

+38

4 . 17 ± 0.20g

0

4 . 63 ± 0 . 12

0.3 2 ± 0 . 09

0. 34 ± 0 . 05

3 . 74 ± 0 . 43£

-19

o. 27g

+2

4 . 86 ± 0.25g

+5

4 . 14 ± 0.25

Sa rine

-150

0

0 . 32 ± 0.09

Saline

-150

90

0.68 ± 0.06f

+112

3.01 ± 0.30£

-36

Ascorbic _
150
acid

0

0 . 33 ± 0 . 02g

+4

4 . 81 ± 0.27g

+43

Ascorbic
-150
acid

90

0 . 43 ± O. Olg

+34

3 . 82 ± 0 . 18g

-18

4 . 68 ± 0 . 20

~inutes .
b

µmoles/g brain ± S. E.

Mean of five mice .

cSaline ( 10 ml/k g body we ight) or ascorbic acid (12 mno les/kg) was
i njected intraperitoneally .
dOHP expo3ure at 60 psig.
e

Percent change compared to salin e controls .
and minus, decrease .

Plus represent s increase

fSignific an tly differ ent from saline controls at the QOS leve l
(Student "t" tes t ) .
gSignifican t ly different from saline+ OHP at the 0 . 05 level (Student
" t" test).
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OHP exposure when compared to saline-treated, room air-exposed animals,
but there was a significant decrease of 18% after 90 min of OHP exposure
(Table 15).

The re was a significant correlation betw2en brain ammonia

levels and the susceptibility of the individual mice to OHP seizures in
ascorbic acid-treated animals (Figure 20).

The correlation coefficients

were -0.76 and -0.86 in the case of latency to convulsion onset and
latency to sei zure complex , respectively (Figure 20) .

There was no sig-

nificant correlation between glutamine levels and seizure susceptibility
(r

=

0.35) in the case of latency to convulsion onset.

between glutmnine levels and seizure susceptibility (r

The correlation
=

0 . 75, p

<

was, however, significant in the case of latency t o seizure complex
(Figur e 21).

0.001)
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Figure 20.

CORRELAT ION BETWEEN BRAIN Afl}10NIA AND SUSCEPTIBILITY TO
HYPERBARIC OXYG EN SEIZURES IN ASCORBIC ACID-TREATED HICE .
O - OHP (60 psig) ,
0 - ascorbic acid (12 nunoles / kg, IP ) .
The animals not convulsing within 90 min were assigned an
arbitrary·convulsion l atency of 90 min . P value repres en ts
rej ection of the hypothesis that the correlation coefficient
(r) equals zero .
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S EIZURE CO PLEX
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r= 0 .15
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P< 0 . 001
I
0

0

0

L ,E CY ( . I )

Figure 21.

CORRELATION BETWEEN BRAIN GLUTAMINE PU D SUSCEPTIBILITY TO
HYPERBARTC OXYGEN SEIZURES IN ASCORBIC ACID-TREATED MICE.
- OHP ( 60 psig), O- ascorbic acid (12 mrnoles / kg , IP ).
The animals not convulsing within 90 min were assigned an
arbitrary convulsion latency of 90 min . P value r epresents
r e j e c tion of the hypothesis that the correlation coefficient
(r) equals zero .
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V.

DISCUSSION

HYPERBARIC OXYGEN CONVULSIONS
That pargyline protected against OHP-induced convulsions (Figure
3) is in agreement with the findings of previous investigators (Blenkarn
~

al. , 1969; Faiman .s:!. al., 1971).

Further, the pretreatment time and

dose of pargyline that provided the greatest degree of protection against
OHP seizures in mice was the same as that employed by Faiman et

~!. ·

(1971).
The pretreatment time and dose of succinic acid that provided maximal protection against OHP-induced convulsions (Figure 10)
as that employed by Woodhall

~

al. (1971).

Blenkarn

~

~-<as

the same

al. (1969) re-

ported that succinic acid was a more effective protective agent against
OHP seizures than was pargyline; however, we did not find this to be
true .

Although equimolar doses of pargyline (0.5 mmoles/kg) and succinic

acid (12 w.moles / kg) were not used in our study or in that of Blenkarn
~ ~·

(1969), comparison of the doses of agent that were most effective

in preventing OHP convulsions showed that pargyline (Figure 3) was more
effective in incre asing the latency to convulsion onset than was succinic
acid (Figure 10).

Both agents in the doses used were, however, approx-

i mately as effective in their ability to increase the latency to seizure
complex .

This discrepancy may be due to the fact that we did not use

fasted animals as did other investigators (Woodhall

~

al., 1971) since

we were able to demonstrate . significar:t protection against OHP
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convulsions after succinic acid treatmen t in non-fasted mice (Figure 10).
DeFeudis and Elliot t (1967) have re po rted that the injection of large
voll.llTles of hypertonic solutions of diverse substances will also increase
tolerance of anima ls to OHP convulsions and thus, obscure the basic
actions of the protective agents being tested.

Although we concur that

our succinic acid solution is indeed hypertonic, we do not consider the
dosage vollllTle inje cted (10 ml/kg) to be a large quantity for use in mice
since it is the vo l l.l111e usually emp loyed in studies conducted in most
laboratories.

Further , injection· of hyp er tonic solutions of NaC l pro-

duc ed the same degree of brain dehy dra tion as did hype rtonic succinic
acid solutions, but the protective effect of NaCl against OHP seizures
was inconsistent compared to th e protective effect of succinic acid
(DeFeudis and Elliott, 1967).

Thus, we feel that possible artifacts due

to fasting or injection of large volumes of hyp er tonic solutions are not
responsible for the protective effects against OHP convulsions in the
case of any of the three agents that we have tested.
Our results also showed that L-·ascorbic acid protected against OHP
convulsions (Figure 17).

Jamieson and Van Den Brenk (1 964), however,

reported a slight decrease in the latency to OHP convulsions after ascorbic acid treatment .

This discrepancy may be due to two factors.

First,

th e dose of ascorbic a cid (1.74 g/kg) used by J am ieson and Van Den Brenk
(19 64) was lower than th e dose of ascorbic acid used in our studies
(2.11 g/kg).

Second, J amieson and Va n Den Brenk (1964) us ed a 10 min

pret reatment time as opposed to the 60 min pretreatment time used in
our studies.

Further, our preliminary results ( appendix Table 7) showed

that a 30 min pr etreatment time was not as effective in reducing the
incidence of

OHP seizures comp ared to th e 60 min pretreatment time.
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In a recent paper, Serrill

et~·

( 1971) reported that ascorbic acid

decreased the latency to OHP convulsions in mice .

Again, the dosage

employed (0.5 g/kg) was lower than that used in our studies.

Also, the

ascorbic acid was given in combination with an equal dose of acetylsalicylic acid (Serrill

~

al. , 1971).

We feel that t hese differences are

due to either the low dosage of ascorbic acid employed or to the fact
that both drugs were given in combination since highe r doses of ascorbic acid (Figure 17) or acetylsalicylic acid (Puglia.£!_ al., 1970)
given individual ly protected against OHP convulsions .
Comparison of the prote ctive effects of pargyline, succinic acid
and ascorbic acid were based on the doses of the agents that were most
effective in decreasing the incidence of OHP convulsions.

That the doses

of ascorbic acid and succinic acid employed in the study were equimolar
is coincidental.
Ascorbic acid increased the latency to convulsion onset (Figure
17) more than did pargy line ( Fig ure 3) or succin ic acid (Figure 10) ,
but all three agents were approximate ly equal in the i r effectiveness
in increasing the latency to the OHP s eiz ure complex .
Since two of the protective agents used in our studies were
acidic when in solution, we undertook to determine if protection aga ins t
OHP convulsions was related to a pH change caus ed by injection of the
acidi c solutions into the peritoneal cavity.

Our results showed that

solutions of pargy line (app endix Table 1), succinic acid ( appendix
Table 4), or ascorbic acid (app endix Table 7) adjusted to pH

6.S

with

2N NaOH or 2N HCl did not decrease the effectiveness of thes e drugs as
protective agents against OHP convulsions.

We, therefore , suggest th a t

the protective effect of thes e agents against OHP convulsions is not due
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to any pH change prod uced by intraperitoneal injection of an acidic
substance or basic substance.
Since OHP exposure decreased body temperature and pargyline enhanced this decrease

(Puglia~

al., 1970), the protective effect of

pargyline against OHP convulsions may have been due to hypothennia.
Since our hyperbaric chamber was not equipped to monitor body temperature, we were not able to measure body temperature in our studies.

It

is kno-;m, hm,; ever , that phenacetin, like pargyline, enhanced the decrea s e in rectal temperature prod'uced by OHP, but phenacet in , unlike
pargyline, did not protect against OHP convulsions

( P ug lia~

al., 1970).

Further evidence against t he protective e£fect of pargyline, succini c
acid or ascorbic acid as being due to thei r ability to enhance OHPinduc ed hypothennia is provided by the finding that acetylsalicylic
acid, which protected against OHP convulsions , partially prevented the
OHP-induced hypothermia

( Pug li a ~

al., 1970).

LETHALITY FOLLOHING HYPERBARIC OXYGEN EXPOSURE
That par gy line increased the number of animals surviving after OHP
exposure (Figure 4) is in agreement with the results of previous i nve stigators (Blenkarn

~al.,

1969).

We have not seen any investigations con-

cerning the effect of succinic acid on post-OHP mortality, but our studies
have shown th at succinic acid, like pargyline, increas ed the number of
animals surviving after OHP exposure (Figure 11).

J amieson and Van Den

Brenk (1964) r eported that ascorbic acid tr eatment did not alter survival times of mice exposed to OHP; however, the se animals were le ft in
the hyperbaric chamber until death , and h ence , the results are not a
measure of post-OHP mor tality.

We have found that ascorbic acid
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decreased post-OHP mortality for about 12 h, but at the end of 72 h the
number of ascorbic acid-treated mice surviving OHP exposure was the same
as that of saline controls (Figure 18).

The possible reasons for this

lack of protection against post-OHP mortality after ascorbic acid treatment will be discuss e d later in relation to the effect of ascorbic acid
on OHP-induced alterations in brain GABA and ammonia levels.

HYPERBARI C OXYGEN-INDUCED PULMONARY D.l\MAGE
To our knowledge, no investigations have been undertaken to study
the effects of pargy line or succinic acid on OHP-induced pulmonary
damage.
Since adrener gic blocking agents decreased OHP-induced pulmonary
to xicity (Gerschman et al ., 1955; Johnson and Bean , 1957) and since MAO
inhibitors can reduce pe ripheral sympathe t ic activity via production of
"false neurotransmitters" (Kopin

~

al., 1965), we ha d a t first thought

that pargyline protection against OHP pulmonar y toxi city (Tables 1 and
2) may have been due to a similar inhibitory effect on peripheral and /o r
central s ympath e tic activity .

The time require d for the production of

"false neurotransmitters" is, however , much longer (Kopin et al., 1965)
than that required for pargyline to exert its protective effect against
OHP-induced pulmonary damage (Tables 1 and 2).

Further, it has already

been established that no apparent correlation existed be tween absolute
levels or turnover rates of brain NE , DA or 5-HT and sus ceptibility to
OHP convulsions ( Blenkarn

~al.,

1969; Fa i man

~t

al ., 1971), and

possibly , this is also true in the case of pulmonary damage .

As men-

ti oned in the literature review , it is not firmly established whether
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pulmonary damage is of central origin and a result of seizure activity
or is due to a direct toxic effect of OHP on the lung .
Both pargyline (Tables 1 and 2) and succinic acid (Tables 6 and 7)
were equally effective in preventing th e OHP-induced increase in lung
weight, lung water content and lung hemoglobin content.
The fact that ascorbic acid prevented the OHP-induced increase in
lung weight (Table 11) is in agreement with previous findings (Jamieson
and Van Den Brenk , 1964).

Comparison of the effec t of ascorbic acid on

OHP -induced pulr:conary damage (Tahles 11 and 12) to the effects of suecinic acid (Tables 6 and 7) or pargyline (Tables 1 and 2) shows that
ascorbic acid was not as effective as the other t wo agents in preventing
the OHP-induced increase in lung weight , lung water content and lung
hemoglobin content.

Possible reasons for this difference will be dis-

cussed later in regard to the ef fect of ascorbic acid on OHP-induced
alterations in brain GABA and runmonia levels.
GAHHA- AMINOBUTYRIC ACID, GLUTANIC ACID DECARBOXYLASE
Al'lD GAHMA-AHINOBUTYRIC ACID TRA1\TSANINASE
The OHP-induced decrease in brain GABA shown in Figures 5, 12 and
19 is in agreement with previous findings (Wood et al., 1963; Wood et

al. , 1966).
To our knowledge, the elevation in brain GABA levels after pargyline treatment (Figure 5) has never been reported before.

This effect

was due to inhibition of GABA degr adat ion by GABA-T (Table 3).

Pargy-

line had no effect on the GABA synthesi zing enzyme, GAD (Table 4).
data ar e in agreement with Popov and Hattheis (1969)

These

who found tha t

other HAO inhibitors elevated brain GABA by inhibiting GABA-T, and these
MAO inhibitors in th e doses used had no effect on GAD activity.
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Succinic acid, on the other hand, elevated GABA levels (Figure 12) by
increasing GABA synthesis (Table 9).

Although the activity of both GAD

(Table 9) and GABA~T (Table 10) were incre ased by succinic acid treatment , GAD was stimulated to a greater degree than was GABA-T.

We estab-

lished a dose-response relationship between the dose of pargyline or
s uccinic acid administered and the degree of elevation in brain GABA
( Figures 5 and 12) although by different mechani s ms .

The ability of

pargyline or succinic acid to prevent t he OHP- ind uced decrease in brain
GABA

(Figures 5 and 12) is responsible , at le as t in part, for the pro-

tective effects of these agents against OHP toxicity.

There was also

a significant correlation b etween OHP seizure susceptibility and brain
GABA levels in pargyline- ( Fig ur e 6) or succinic acid-treated mice (Figure 13) .

Further support for decrea sed levels of GABA bein g involved

in OHP toxicity is provided by the findings that GABA administration
decreased OHP convulsions (Wood
~

~

al. , 1963) and pulmonary damage (Wood

al., 1965).
Results obtained using succinic acid may be explained in rel at ion

to ATP availability.
(Woodhall et

~·

Since ATP is decreased during OHP exposure

, 1971) and both GAD and GABA-T are Pyr P requiring en-

zymes (Baxter, 1970), OHP may inhibit pyridoxal kinase thus decreasing
the availability of the Pyr P cofactor.

That OHP inhibits GAD prefer-

entially may be explained by the fact tha t the cofactor is only loose ly
bound to GAD whereas Pyr P has a greater affinity to GABA-T (Baxter ,
1970) and, the refo re , decreased Pyr P availability might be expected to
have a greater effer.t on the activity of GAD tha n on that of GABA-T .
Succi nic acid, by eeans of increasing ATP levels , could increase Pyr P
availabil ity and consequently, elevate GAD and GABA-T activity.
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Succinic acid could also maintain normal ATP leve ls during OHP exposure
and thus, prevent the OHP-induced dec rease in GAD activity.
Pargyline, like other MAO inhibito rs (Tapia and Pasantes, 1971),
may inhibit GABA-T by preventing combination of the Pyr P cofactor with
the enzyme thus decreasing GABA-T activity.

That pargyline preferenti-

ally inhibited GABA-T and was without effect on GAD may be explained in
light of the fact that GAD and GABA-T have a different subcellular
localiza tion (Baxter , 1970).

For this reason, pargy l i n e I!lay not be

allowed access to the subcellular compartment containing GAD and cannot ,
th erefore , inhic.i t GAD.
Although our experiments were all

i~

vivo studies and may not ac-

curately ref lect ce llula r events, they do enable us to gain some insight
as to possible biochemical events and enable us to make the preceding
spe culations .

Substantiation of . these speculations would require ex t en-

sive research on the in vitro aspects of OHP toxic ity and the effects of
pargyline , succinic acid and ascorbic acid thereon.
The ability of pargyline to e levate brain GABA may at first seem
paradoxical since pargyline is used as an antidepressant , whereas GABA
has neuronal inhibitory properties.

It may be that GABA is not involved

in mood, and pargyline's effect on GABA is, therefore, not related to
pargy line 's ability to combat depres sion.

Also , our study involved the

administration of only one dos e of pargyline and is, therefore, shortterm in nature, whereas chronic ad ministration of pargyline is requir ed
for this drug to exhibit it s antidepres sant effect.
Other factors are involved in the production of OHP toxicity as
indicated by the fact that ascorbic acid pro te cted against OHP toxicity
(Figures 17 and 18; Tables 11 and 12) but did not increase GABA levels
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or prevent the OHP-induced decrease in brain GABA levels (Figure 19).
Further, there was no correlation b etween GABA leve ls and OHP seizure
susceptibility in ascorbic acid-treated mice .
AI1MONIA AND GLUTAMINE
The elevation in brain ammonia levels during OHP exposure
(Gersheno vich and Krichenskoya, 1954; Sz am , 1969) is though t to be due
to inhibition of glutamine synthet ase . (Ger shenovich

~

al., 1963).

Glu-

tamine synth etase catalyzes the combina tion of glutamic acid and ammonia
to form glutamine (Fig ur e 1) and this reaction is, therefore, a means
of ammonia det oxication in CNS .

This is believed to be the main path-

way for ammonia detoxication in brain (see Weil-Halherbe, 1962) especiall y since th e C.:IS does not have all the enzymes of the urea cycle as does
the liver (Katanrn:na

~

al. , 1965).

The fact that the increase in brain ammonia levels during OHP
exposure (Tables 5, 10 and 15) was greatest at the time of maximal
sei zure activity (Fig ures 3, 10 and 17) anrl that administration of ammonium salts produced convulsions
~

(S alvatore and Bocchini, 1961; Ugart e

al, 1968) and pulmonary damage (Ktlnig and Ktlnig, 1%9) indicates that

el evated brain ammonia levels may be involved in the etiology of OHP
toxicity .

Support for this hypothesis also lies in the ability of par-

gyline (Table 5), succinic acid (Table 10) or ascorbic acid (Table 15)
to lessen the OHP-induced elevation in brain am!non i a and to prot ec t
again s t OHP toxicity .

Further, there was a significant correlation be-

tween OHP seizure susceptibility and brain amfl1on i a levels in pargyline-,
succinic acid- or ascorbic acid-treated mice (Figures 8, 15 and 20).
The decrease in brain g lut amine levels during OHP exposure (Table 5, 10
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and 15) also correlated wel l with OHP seizure susceptibility in pargyline-, succinic acid- or ascorbic acid-tre ated mice (Figures 9, 16 and

21).

This decrease is t h ough t to be due to inhibition of glutamine syn-

thetase (G ershenovich

~al.,

1963); hence, the ability of the brain to

detoxify ammonia was impaired.
The source of this ammonia could be, in part, due to increased MAO
activity in the presence o f elevat ed oxygen t ension (Novick , 1966).
This would incre2se various deamination reactions resulting in the observed elevation in brain anunonia levels and decrease in brain DA , NE
and 5-HT during OHP exposure (Faiman et a l., 1971).

Pargyli_ne offset

this OHP-induc ed arrunonia. elevation (T able 5) possibly by prevent ing the
OHP-induced incre r.ts e in HAO activity.
Succini c acid prevented the OHP-induced decrease in brain ATP
levels (Woodha ll

~

a l. , 1971) and may, therefore, pr event OHP-induced

inhibition of glutamine synthetase if the enzyme inhibition is due to
decrea s ed ATP availability.
Ascorbic acid, like succinic acid, can supply reducing equivalents
to the mitochondrial r espirato ry c hain (Mapson , 196 7) and could, ther efore, als o prevent the OHP-induced decrease in brain ATP levels.

Both

suc cinic acid a nd ascorbic acid may in this manner allm·1 the brain ' s
anunonia detoxicat ion pathway to function norma lly during OHP exposure
and consequently , prevent the OHP-induced build up in brain ammon i a and
decrease in br ain glutamine levels.
RELATIONSHIP BETl-.TEF.N BRAIN AHMONIA
AND GAfJM!,·-AHINOB1.JTYRIC ACID

As c an be seen in Figure 1, both ammonia and GABA are intima t ely
related in that they have Lhe common precursor glutamic acid.

Although
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pargyline, succinic acid or ascorbic acid all protected against OHP convulsions, asco rbic acid was not as effective against th e tot a l OHP toxicity syndrome. This, and the fact that all thre e agents lessened the
OHP-induced elevation in brain ammon ia, but ascorbic acid, unlike pargyline and succinic acid, did not prevent the OHP-induced decrease in
brain GABA, may point to a relationship between ammonia and GABA in the
etiology of OHP toxicity .

We feel that decrea sed br ain GABA levels and

incr eased ammonia levels a r e primarily res pons ible for the OHP toxicity
syndrome .
There is another common link between th ese protective agen ts in
that they all have an effect on the mito chondria whose function is i mpaired early in the course of OHP toxicity (Haugaard , 1968).

Mi tochon-

drial dys f unction could, therefore, a c count for the reported decrease
in brain ATP levels (Woodhall et al., 1971) and cons equent inhibition
of glutamine synthetas e (Gersh enov ich et al.," 1963) and pyridoxa l kinase
(Baxter, 1970).

This i nhibition could, there fore, account for the

altered brain GABA and ammonia me t abolism observed in our studie s and
by others (Wood et al. , 1966; Wood et al. , 1969; Gershenovich and
Krichenskoya, 1954 ; Gershenovich

~al.,

1963).

If increased HAO activity contributes to mitochondrial dysfunction,
then pargyline could prevent this effect.

Also,

}~.O

is ass ociated with

the outer lea f of the mitochondrial memb rane (S otto casa , 1967; Schnaitman
~ ~·,

196 7) and pargyline could maintain mito chondrial int egrity by

binding to this membrane-associated enzyme pos sibly stabilizing the
mito chondria l menib r ane .

In eit her case, stabilization of mitochondrial

function could be the result, and consequently , normal ATP leve ls could
b e maintained.
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Normal ATP levels are maintained after succinic acid treatment in
OHP-exposed animals

(Sander s~~ ·,

1966), and this may also be true

in the case of ascorbic acid since both agen ts can supply r ed ucing equivalents to the mitochondrial res piratory chain for ATP production.

The

decreased protective effect of ascorbic acid compared to succinic acid
could be due to the fact that ascorbic acid enters the respiratory chain
at a later step than does succinic acid (Mapson , 1967) and consequent ly,
would not provide for as much ATP produc tio n as would succinic acid .
Therefore , although decreased brain GABA and increased arrunonia
levels may be responsible for the actual OHP toxi c

syndro~e ,

the common

underlying cause of thes e biochem ical changes in GABA , ammon ia and glutamine and GABA enzymes could be due to decreased ATP production or
availability, and pargyline, succinic acid or ascorbic acid could exert
their protective effect by maintaining normal ATP levels during OHP
exposure.
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VI .
1.

SUMMARY AND CONCLUSIONS

Hyperbaric oxygen produced convulsions and post-OHP mortality and
increased weight, water content and hemoglobin content of the lungs.

2.

Pargyline, succinic acid or ascorbic acid protected against all of
the above aspects of OHP toxicity to varying degrees .

The doses of

parg yline and succinic acid that were maximally effective in protecting against OHP convulsions were approxi mately equal in their
ability to reduce the severity of the rest of the OHP toxicity syndrome .

The dose of ascorbic acid providing maximal protection

against OHP convulsions was as effective as was pargyline or succinic acid in decreasing OHP convulsions but was less effective in
r educing the severity of the other aspects of oxygen poisoning.
3.

OHP exposure decreased brain GABA levels and brain GAD activity but
had no effect on GABA-T activity .

Both pargyline and succinic acid

i ncreased brain GABA levels and prevented the OHP-induced decrease
in brain GABA.

The ability of these agents to elevate brain GABA

correlated well with the dose of the agent administered.

There was

a lso a correlation between GABA levels and OHP seizure susceptibility
i n pargyline- or succinic acid-treated mice.
4.

Pargyline elevated brain GABA and prevented the OHP-induced decrease
in GABA via inhibition of GABA-T activity in mice exposed to room
air or OHP .

Pargyline had no effect on GAD activity nor did it pre-

v ent the OHP-induced decrease in GAD activity.
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5.

Succinic acid increased GABA-T and GAD activity in room air-exposed
mice .

6.

Succinic acid increased brain GABA levels by increasing the activity
of GAD .

The i ncrease in GABA-T activity after succinic acid was

l e ss t han t ha t of GAD , and GABA-T activity returned to contro l l evels
during OHP exposure while GAD activity remained slightly elevated .
7.

Ascorbic acid had no effect on brain GABA levels nor did it prev-cnt
the OHP-induced decrease in brain GABA.

Ascorbic acid had no effect

on the GABA enzyw.es nor did it prevent the OHP-induced decreas2 in
brain GAD aclivity .

There was no correlation between GABA levels

and OHP seizure susceptibility in ascorb ic acid-treated mice .
8.

Hyperba r ic oxygen exposure increased bra in

a~monia

and decreased

brain glutamine levels .
9.

Pargyline, succinic acid or ascorbic acid had no effect on brain
ammonia or glut amine levels in room air-exposed mice .

10.

Pargyline, succinic acid and ascorbic acid markedly reduced the
OHP-induced increase in brain ammonia levels and also reduced the
degree to which brain glutamine levels Fere decreased by OHP exposure .

11.

There was a correlation between brain anunonia levels and OHP seizure
s usceptibility in pa rgyline- , si:ccinic acid- or ascorbic a.cidt reated mice .

This was also true for gJ ctmainc leve ls and OHP sei-

zure suscep t ibility .

12.

The effective ness of pargyline , succinic acid and ascorbic acid as
protective agent s against OHP toxicity is related to their ability
t o alter the deleterious effects of OHP exposure on brain ammonia
and GABA metabolism .
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Table 1.

a

Dose
(mg/kg)

EFFECT OF Pr-E:TREATHENT TIME AND DOSE OF PARGYLINE ON
HYPERBARIC OXYGEN CONVULSIONS

Pretreatment
time (min)

10

Minutes of OHP Exposure
30
40
so 60 70

20

N

80

90

% Convulsed

CO NVUL SIO ~l

ONSET

0

30

30

0

23

37

60

70

93

100

100 100

so

30

7

0

13

13

43

S7

86

86

86 100

100

30

26

0

0

0

19

19

23

3.5

3S

39

200

30

13

0

0

lS

lS

23

23

46

60

60

100

60

7

0

c

lS

13

29

43

43

S7

71

100

120

10

0

0

10

20

20

40

60

70

70

100

240

7

0

0

13

29

29

S7

71

71

86

lOOb

30

7

0

0

0

13

13

29

29

29

43

SEIZURE COMP LEX
0

30

30

0

0

7

23

Sl

81

100

50

30

7

0

0

0

13

29

29

57

71

•11

100

30

26

0

0

0

4

.4

8

12

12

12

200

30

13

0

0

0

8

lS

23

38

54

54

100

60

7

0

0

0

0

13

29

43

57

57

100

120

10

0

0

0

10

10

20

20

20

40

100

240

7

0

0

0

13

13

29

29

57

S7

30

7

0

0

0

13

13

13

13

29

29

lOOb

•

100 100

aPa rgyline or saline (10 ml/kg body weight) was inj ected intraperitoneally.
bPargyline solution was adjusted to pH 6. S with 2

NaOH .
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Table 2.

ALTERATION OF MOUSE BRAIN GAHMA-AHINOBUTYRIC ACID BY
PARGYLINE AND HYPERBARIC OXYGEN
Treatment

a . b
Drug-time

•

oupc
. b
n -time

µmoles GABA/g brain
(Mean ± S. E . ) e

% Change

Saline

-120

0

2 . 19 ± 0 . 065

Sn line

-60

30

1. 85 ± 0.108

<0.05

-16

Saline

-90

60

1. 43 ± 0 . 124

<0 . 005

-32

Saline

-120

90

1. 43 ± 0 . 142

<0 . 005

-35

Pargyline

-30

0

2.47 ± 0.057

<0.01

+13

Pargyline

-60

0

2.83 ± 0.142

<0 . 005

+30

Pargyline -120

0

3.12 ± 0.081

<0.001

+42

Pargyline

-60

30

2.33 ± 0 . 064

>0.05

+6

Pargyline

-90

60

2 . 46 ± 0.077

>0 . 05

+13

Pargyline -120

90

2. 35 ±

o. 091

>0.05

+7

aSaline (10 ml/kg body weight) or pargyline (100 mg /kg ) was injected
intraperitoneally.
bM. 1nutes.
.
c
OHP exposure was at 60 psig.
dSignificantly different from saline controls at the 0.05 level
( Student "t" test).
eEach value represents mean of six mice .
f

Plus repres en ts increase and minus, decrease .

f
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Table 3.

EFFECT OF VARIOUS DOSES OF PARGYLINE ON HOUSE
BRAIN GAffHA-AMINOBUTYRIC ACID

Treatmenta

µmoles GABA/g brain,
Mean ± S. E. (N)

% Change

Saline

2.08 ± 0.079 (5)

Pa-::-gyline
( 25 mg/kg)

2.24 ± 0.089 (5)

>0.05

+8

Pargyline
(SO mg/kg)

2.48 ± 0.094 (5)

<0.02

+19

Pargyline
(100 mg/kg)

2. 7 6 ± 0. 08 9 ( 6)

<0.001

+33

Pargyline
(2 00 mg/kg)

2.91 ± 0.107 (5)

<0 .001

+40

aSaline or pargyline (10 ml/kg body weight) was injected
in traperitoneally 120 min prior to sacrifice. Dose is
given in parentheses.
bValues were obtained from duplicate samples.
cSignificantly different from saline controls at the 0.05
level (Student "t" test).
d

Plus represents increase.

d
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Table 4.

EFFECT OF PRETREAT 1ENT TIME AND DOSE OF SUCCI NI C ACID ON
HYP ERBARIC OXYGEN CONVULSIONS

10

a

Dose
Pretreatment
(mmoles/kg) time (min)

20

:Minutes of OHP Exposure
40
60
50
30
70

N

80

90

% Convulsed

CONVULSION ONSET
0

60

20

0

30

40

70

80

90

100

100

100

6

60

7

0

0

13

13

43

43

57

71

71

12

60

18

0

6

11

39

44

50

57

57

57

15

60

7

0

13

13

29

43

43

57

57

57

12

30

7

0

13

13

13

29

57

71

71

71

12

120

7

0

0

13

29

29

29

43

57

57

12

240

7

0

13

29

29

57

57

71

86

86

12b

60

7

0

0

0

13

29

43

43

43

57

SEIZURE cmlPLEX
0

60

20

0

0

0

30

80

90

90

100

100

6

60

7

0

0

0

13

29

29

43

43

57

12

60

18

0

0

0

6

11

11

22

33

33

15

60

7

0

0

0

0

0

13

43

43

43

12

30

7

0

0

0

13

13

57

71

71

71

12

120

7

0

0

0

13

13

13

29

29

43

12

240

7

0

0

0

29

29

43

57

57

71

12b

60

7

0

0

0

13

13

13

29

29

29

aSuccinic acid or saline (10 ml/kg body weigh t) was inj ec ted intraperitoneal ly.
bs UCClnlC
· · aci· d solution was adjust ed to pH 6.5 with 2N HCl.
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Table 5.

ALTERATION OF HOUSE BRAI ~ GAflNA-1'..HINOBUTYRI C ACID BY
SUCCINIC ACID AND HYPERBARIC OXYGEN

Treatment
a . b
OHPc-time
. b
Drug-tliile

µmoles GABA/g brain
(Mean ± S . E. ) e

% Change

Saline

-150

0

1.97 ± 0.037

Saline

- 90

30

1.72 ± 0.072

<0 .005

-13

Saline

-12 0

60

1. 48 ± 0. 06 7

<0.001

--2 5

Saline

-15 0

90

1. 33 ±

o. 080

<0 .001

-33

Succinic
acid

-60

0

2 .40 ± 0.097

<0.005

+22

Succinic
acid

-9 0

0

2.58 ± 0.128

<0 .005

+31

Succinic
-150
acid

0

2.36 ± 0.061

<0 .001

+20

-90

30

2.42 ± 0.158

<0.02

+23

Succinic
acid
-120

60

2.23 ± 0.068

<0.01

+13

Succinic _
150
acid

90

1. 91 ±

o. 049

>0 .05

-3

Succinic
acid

aSaline (10 ml/kg body weight) or succinic acid (12 mmoles/kg) was
injected intraperitoneal ly.
bM.inutes.
cOHP exposure was at 60 psig.
dSignifican tly different from salin e controls at the 0.05 level
(Student "t" test).
eEach value represents mean of six mice.
fPlus repr esent s increase and minus, de crease .

f
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Table 6.

EFFECT OF VARIOUS DOSES OF SUCCINIC ACID ON MOUSE
BRAIN GAf1MA-A11INOBUTYRIC ACID

Treatmenta

µm oles GABA/g brain,
mean ± S.E. (N)

% Change

Saline

2.03 ± 0.063 (5)

Succi nic acid
(3 mmo les/ kg )

2 . 12 ± 0.103 (5)

>0 .05

+4

Succin i c acid
(6 mooles/kg)

2 . 37 ± 0 .098 (5)

<0.01

+17

Succinic acid
(12 mmoles/kg)

2. 63 ± 0.135 (5)

<0 .005

+30

Succinic acid
(24 mmoles/kg)

3.25 ± 0.09 8 (4)b

<0.0005

+60

d

aSaline or succ1n1c acid (20 ml/~g body weight ) was injected
intraperitoneally 90 min prior to sacrifice. Dose is gi~en
in parentheses.
bone out of five mice was dead prior to sacrifi c e and the .remaining fo ur appeare d si ck .
cSignificantly different from saline controls at the 0.05
level ( Student "t" test).
d

Plus represents increase .
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Table 7.

EFFECT OF PRETREATilENT TIME AND DOSE OF L-ASCORBIC ACID ON
HYPERBARIC OXYGEN CONVULSIONS

a

Dose
Pretreatment
(mmoles/kg) time (min)

10

20

Minutes of OHP Exposure
30
40
so 60 70

80

90

% Convulsed

N
CONVULSION ONSET

0

60

19

0

42

47

53

74

100

100

100

100

6

60

7

0

13

43

71

71

71

71

71

71

12

60

18

0

0

0

17

17

28

28

28

28

15

60

7

0

0

0

13

29

29

29

43

43

12

30

7

0

43

43

43

57

57

57

57

57

12

120

7

0

0

0

13

13

29

29

29

43

12

240

7

0

0

13

13

29

29

43

43

43

12b

60

7

0

·o

0

13

13

13

13

29

29

SEIZURE COMPLEX
0

60

19

0

0

5

26

74

95

100

100

100

6

60

7

0

0

13

29

29

71

71

71

71

12

60

18

0

0

0

0

6

6

17

17

17

15

60

7

0

0

0

0

13

13

13

29

29

12

30

7

0

0

13

13

29

29

29

43

43

12

120

7

0

0

0

13

13

13

29

29

29

12

240

7

0

0

13

13

13

29

29

43

Lf 3

12b

60

7

0

0

0

0

13

13

13

13

29

aAscorbic acid or saline (10 ml/kg body weight) was injected intr a peritoneally.
bAscorbic acid solution was adjusted to pH 6.5 wi th 2N NaOH .
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Table 8 .

ALTERATION OF MOUSE BP-A.IN GAf!NA-AHINOBUTYRIC ACID BY
ASCORBIC ACID AND HYPERBARIC OXYGEN

Treatment
OHPc-time
. b
a
.
Drug-time b

µmoles GABA/g brain
(Mean ± S. E. )e

% Change

Saline

-150

0

1.97 ± 0.037

Saline

-90

30

1.72 ± 0.072

<0 . 005

-13

Saline

-120

60

1.48 ± 0.067

<0.001

-25

Saline

-150

90

1.33 ± 0.080

<0.001

- 33

Ascorbic
acid

-60

0

2 . 02 ± 0 . 060

>0 . 05

+3

Ascorbic
acid

-90

0

2.03 ± 0.067

>0.05

+3

Ascorbic
acid

-150

0

2.01 ± 0 . 094

>0.05

+2

Ascorbic
acid

-90

30

1. 78 ±

o. 072

<0.05

-10

Ascorbic
acid

-120

60

1. 75 ± 0 . 185

<0.05

-11

Ascorbic
acid

-150

90

1.31 ± 0.099

<0.001

-34

f

aSali ne (10 ml/kg body weight) or L-ascorbic acid (12 mmoles/kg) was
injected intraperiton ea lly .
bM.
nnutes.
cOHP exposure was at 60 psi g .
dSignificantly different fr om saline controls at the 0 . 05 level (Student "t" test) .
eEach value repres ents mean of six mice.
f

Plus represents incr ease and minus, decrease.

